[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nasopharyngeal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nasopharyngeal-carcinoma":32},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,109,0,25,[9,62,75,102,131,164,191,217,248,278,303,322,342,366,385,407,430,450,473,503,524,549,578,600,621],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":41,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100054087","phase-1-docetaxel-and-sx-682-in-recurrentmetastatic-head-and-neck-squamous-cell-carcinoma-salivary-gland-carcinoma-and-advanced-prostate-cancer-100054087",false,"NCT07667400","Docetaxel and SX-682 in Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer","Phase I\u002FII Trial of Docetaxel and SX-682 in Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer","* INCLUSION CRITERIA:\n\nAll Participants\n\n* Age \\>= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) \\\u003C= 2\n* Participants must have adequate organ and marrow function as defined below:\n\n  * ANC \\>= 1,500\u002FmcL\n  * Hemoglobin (Hgb) \\>= 9 g\u002FdL\n  * Platelets (PLTs) \\>= 100,000\u002FmcL\n  * Creatinine clearance \\>= 50 mL\u002Fmin (by Cockroft-Gault formula)\n  * Total bilirubin \\\u003C= 1.5 x iULN (\\\u003C= 3 x ULN in participants with known\u002Fsuspected Gilbert s disease)\n  * ALT\u002FAST \\\u003C= 2.5 x iULN\n  * Activated partial thromboplastin time (aPTT) \\\u003C= 1.5 x iULN\n* Contraception as follows:\n* Women of child-bearing potential (WOCBP) must agree to use an effective method of contraception (barrier, hormonal, intrauterine device \\[IUD\\], surgical sterilization, abstinence) prior to study entry, for the duration of study treatment, and for up to 2 months after discontinuation of the study drugs. A participant may request a male partner to use an effective form of contraception to fulfill this requirement.\n* Men able to father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to 4 months after discontinuation of the study drugs. A participant may request a female partner to use an effective form of contraception to fulfill this requirement. Men able to father a child must not freeze or donate sperm within the same period.\n* Nursing participants must be willing to discontinue nursing from study treatment initiation through one week after the last dose of study drugs.\n* Participants must be able to swallow oral medications.\n* Human immunodeficiency virus (HIV)-infected participants must have undetectable viral load (VL) and be on effective anti-retroviral therapy within 4 weeks prior to the study treatment initiation and have no history of opportunistic infections or Castleman s disease within 12 months prior to the study treatment initiation.\n* Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV VL.\n* Participants with evidence of chronic hepatitis C virus (HCV) infection must have undetectable HCV VL.\n* Participants must be able to understand and willing to sign a written informed consent document.\n\nParticipants with HNC\n\n* Histologically confirmed HNSCC (including oral cavity, oropharynx, larynx, hypopharynx, paranasal sinuses, nasopharynx) or SGC (including ACC and non-ACC) and recurrent\u002Fmetastatic (R\u002FM) or advanced incurable disease.\n* Prior treatment as follows:\n\n  * Participants with R\u002FM HNSCC must have prior systemic treatment (platinum-based chemotherapy and\u002For anti-PD(L)1 treatment).\n  * Participants with R\u002FM SGC may have any number of prior systemic treatment lines; prior systemic treatment not required for participation.\n  * Participants must not have received systemic anticancer treatment within 3 weeks prior to first treatment administration. Note: Treatment-related toxicities must have resolved to Grade \\\u003C2 or be minimal and not constitute a safety risk. Participants with SGC previously treated with hormonal therapies (e.g., drugs targeting the androgen receptor) may continue these drugs concomitantly with study therapy. Participants with bone metastases or hypercalcemia on intravenous bisphosphonate medications, denosumab, or similar agents, are eligible to participate and may continue this treatment.\n* Presence of \\>= 1 measurable lesion by RECIST v 1.1 criteria.\n\nParticipants with mCRPC\n\n* Documented histopathological confirmation of prostate cancer. If no pathologic report or specimen is available, participants may enroll with a history of clinical course consistent with the disease.\n* Participants must have mCRPC, defined as at least one lesion on TC-99 bone scan or at least one lesion that is measurable per RECIST 1.1.\n* Participants must need ADT as part of their cancer therapy (unless previous orchiectomy)\n* Castrate testosterone level (\\\u003C50 ng\u002Fdl or 1.7 nmol\u002FL)\n* Prior treatment as follows:\n\n  * DTX for mCRPC is allowed but participants must not have had progression while on docetaxel or within 3 months after completing DTX for mCRPC\n  * Participants must have been previously treated with modern anti-androgens such as abiraterone, enzalutamide, apalutamide, or darolutamide.\n* Progression defined as two consecutive rising PSA values at least 1 week apart or radiographic evidence of progression seen on computed tomography (CT) scan or TC- 99 bone scan.\n* Toxicities related to prior therapy, including surgery and\u002For radiation, must have resolved to \\\u003C Grade 1 per CTCAE v.6.0.\n\nEXCLUSION CRITERIA:\n\nAll participants\n\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to DTX, SX-682, or other agents used in study (e.g., polysorbate 80).\n* Known active brain metastases. Note: Participants with previously treated brain metastases are eligible if imaging at least four weeks prior to first trial treatment shows no evidence of progression and neurologic symptoms have resolved, have no new or enlarging brain metastases, and are not using glucocorticoids for at least a week prior to first trial treatment\n* Participants must not have received other investigational agents within 3 weeks prior to the first dose of the study drug(s).\n* Participants must not have received major surgery within 14 days prior to the first drug administration (minimally invasive procedures such as diagnostic biopsies are permitted). If participant underwent major surgery, they must have recovered adequately (according to the Principal Investigator) from the toxicity and\u002For complications from the intervention prior to starting study treatment.\n* Treatment (systemic) with any medications or substances that are moderate or strong inducers or moderate or strong inhibitors of cytochrome P450 (CYP3A4) listed at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-druginteractions- table-substrates-inhibitors-and-inducers#table2-2,table3-3,table5-2 within 2 weeks or 5 half-lives (whichever is shorter) prior to the start of the study treatment.\n* Prior or concurrent malignancy whose natural history or treatment has potential to interfere with the safety or efficacy assessment of the study treatment.\n* Participants with serious uncontrolled intercurrent illness evaluated by medical history, electrocardiogram (EKG), and physical exam that would unacceptably increase risk for the participant or impair the ability to evaluate the endpoints of the study or that would limit compliance with study requirements.\n\nParticipants with HNC\n\n* Participants must not have received large-field radiotherapy within 2 weeks prior to first treatment administration. All residual treatment-related toxicities must have resolved to Grade \\\u003C2 (except for radiation-induced xerostomia\u002Fdysgeusia) or be minimal and not constitute a safety risk.\n* Positive pregnancy serum or urine beta-human chorionic gonadotropin (beta-hCG) test\n\nParticipants with mCRPC\n\n* Use of other medications for urinary symptoms including 5-alpha reductase inhibitors (finasteride and dutasteride) and alternative medications known to alter PSA (e.g., phytoestrogens and saw palmetto) within 1 week prior to the study treatment initiation.\n* Cancer related neuropathy at screening\n* Baseline QTcF \\>= 470 ms","ALL","18 Years","120 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Background:\n\nHead and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States. Survival rates for these cancers are lower than 50% if they spread to other parts of the body or return after treatment. Better treatments are needed.\n\nObjective:\n\nTo test a new drug (SX-682), combined with an approved drug (docetaxel, or DTX), in people with HNCs or prostate cancer.\n\nEligibility\n\nPeople aged 18 years and older with an HNC or prostate cancer that has returned after treatment or has spread.\n\nDesign:\n\nParticipants will be screened. They will have blood tests, imaging scans, and a test of their heart function. A tissue sample (biopsy) of the tumor may be taken.\n\nParticipants will take the study drugs in 3-week cycles. SX-682 is a tablet taken by mouth twice a day from Days 1 to 11 of each cycle. Participants will get a supply of the drug to take home. DTX is given on Day 8 of each cycle through a tube attached to a needle inserted into a vein in the arm. Participants will come to the clinic on Days 1 and 8 of every cycle. They will take both drugs for up to 6 cycles.\n\nParticipants will have follow-up visits 1 week and 1 month after they finish taking the drugs. Follow-ups will continue every 3 months for 2 years. Then they will have phone or email check-ins twice a year until 5 years have passed.",[29,30,31,32,33,34,35,36,37,38,39,40],"Head and Neck Cancer","Head and Neck Squamous Cell Carcinoma","Paranasal Sinus Neoplasms","Nasopharyngeal Carcinoma","Oropharyngeal Squamous Cell Carcinoma","Hypopharyngeal Cancer","Carcinoma of Larynx","Oral Squamous Cell Carcinoma","Salivary Gland Cancer","Adenoid Cystic Carcinoma","Prostate Cancer","Metastatic Castration Resistant Prostate Cancer",[42,43,44,45,46,47,48],"Solid Tumors","Infusion","Chemotherapy","Carcinoma","Head and Neck","Prostate","molecule inhibitor","NOT_YET_RECRUITING","2026-07-10",{"date":52,"type":53},"2026-07-13","ACTUAL",{"date":55,"type":22},"2026-07-16",{"date":57,"type":22},"2037-10-01",{"name":59,"class":60},"National Cancer Institute (NCI)","NIH",1,{"id":63,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":27,"conditions":66,"keywords":67,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":74,"locationsCount":61},"100643883",{"count":21,"type":22},[25,26],[29,30,31,32,33,34,35,36,37,38,39,40],[42,43,44,45,46,47,48],"2026-07-01",{"date":70,"type":53},"2026-07-02",{"date":72,"type":22},"2026-07-07",{"date":57,"type":22},{"name":59,"class":60},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":61},"100561625","phase-2-gemcitabine--docetaxel--toripalimab-induction-in-epstein-barr-virus-ebv-associated-nasopharyngeal-carcinomanpc-100561625","NCT06592599","Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)","A Safety, Feasibility and Efficacy Study of Gemcitabine Plus Docetaxel Plus Toripalimab (GDT) Induction as Part of a Curative Sequential Chemoradiation for Patients With Locoregional EBV Associated Nasopharyngeal Carcinoma (NPC)","Inclusion Criteria:\n\n1. Eligible disease(s) \u002F stage(s): Locoregionally advanced EBV positive NPC (T3-4, any N OR any T, N1-3. No M1) per AJCC v 8\n2. Prior therapy: None for NPC permitted\n3. Life expectancy: 3 months at least\n4. Contraception requirements: Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control during treatment with toripalimab and for 4 months after the last dose.\n5. ECOG Performance Status of 0,1, or 2\n6. Age: At least 18 years old.\n\n   CBC\u002Fdifferential obtained within 21 days prior to day 1 of treatment, with adequate bone marrow function defined as follows:\n7. Absolute neutrophil count (ANC) ≥ 1,500 cells\u002Fmm3\n8. Platelets ≥ 100,000 cells\u002Fmm3;\n9. Hemoglobin ≥ 8.0 g\u002Fdl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g\u002Fdl is acceptable.);\n\n   Adequate hepatic function within 21 days prior to day 1 of treatment, defined as follows:\n10. Total bilirubin ≤ 1.5 x institutional ULN;\n11. AST and ALT ≤ 1.5 x institutional ULN;\n\n    Adequate renal function within 21 days prior to day 1 of treatment, defined as follows:\n12. Serum creatinine ≤ 1.5 mg\u002Fdl or calculated or measured creatinine clearance (CC) ≥ 50 ml\u002Fmin\n13. Negative serum pregnancy test within 14 days prior to day 1 of treatment for women of childbearing potential\n14. Ability to understand and the willingness to personally sign the written IRB approved informed consent document.\n\nExclusion Criteria:\n\n1. Prior systemic anticancer treatment for NPC\n2. Prior radiation to head and neck region or regions necessitating overlapping fields\n3. Concurrent use of any anti- cancer treatment, standard, alternative or investigational.\n4. History of allergic reactions to any agents in this study\n5. Autoimmune disease or organ transplant which in the judgment of the PI would increase the risk of immune checkpoint inhibition.\n6. Pregnant or breastfeeding\n7. Severe, active co-morbidity, defined as follows:\n\n   * Major medical or psychiatric illness, which in the investigator's opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy;\n   * Unstable angina and\u002For uncontrolled congestive heart failure within past 6 months;\n   * Myocardial infarction within the last 6 months;\n   * Current acute bacterial or fungal infection requiring intravenous antibiotics; note that patients receiving IV antibiotics or currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible.\n   * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to day 1 of treatment;\n8. Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive\n9. Patients with hearing loss assessed to be primarily sensorineural in nature, requiring a hearing aid, or intervention (i.e. interfering in a clinically significant way with activities of daily living); a conductive hearing loss that is tumor-related is allowed\n10. ≥ grade 2 peripheral sensory neuropathy",{"count":83,"type":22},24,[26],"The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.",[32],[88,89,90],"gemcitabine","docetaxel","toripalimab","RECRUITING","2026-06-19",{"date":94,"type":53},"2026-06-23",{"date":96,"type":53},"2024-09-03",{"date":98,"type":22},"2029-01",{"name":100,"class":101},"Stanford University","OTHER",{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":61},"100568531","induction-chemotherapy-response-guided-radiation-for-ebv-associated-nasopharyngeal-carcinoma-100568531","NCT06682442","Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed (from primary lesion and\u002For lymph nodes) nasopharyngeal carcinoma.\n* Participants must have Epstein Barr virus (EBV)-associated nasopharyngeal carcinoma, defined as detectable (\\> 0 copies\u002FmL) circulating plasma EBV DNA on a qualitative or quantitative polymerase chain reaction (PCR)-based test.\n* Stage III-IVA disease (American Joint Committee on Cancer \\[AJCC\\], 8th edition \\[ed.\\]) with no evidence of distant metastasis at the time of diagnosis based upon all 3 of the following minimum diagnostic workup criteria:\n\n  * History\u002Fphysical examination by a medical oncologist or clinical oncologist or radiation oncologist or otolaryngology (ENT);\n  * Evaluation of tumor extent with either one of the following:\n\n    * MRI with contrast of the face, nasopharynx, and neck or CT with contrast of the face, nasopharynx and neck with ≤ 3 mm contiguous slices and bone windows to evaluate base of skull involvement; or\n    * MRI of the nasopharynx and PET\u002FCT (with contrast) of the neck\n  * Imaging to rule out distant metastasis:\n\n    * CT scan with contrast of the chest and abdomen (required) and the pelvis (optional) or a total body PET\u002FCT scan (non-contrast PET\u002FCT is acceptable); and\n    * Only if clinically indicated: Bone scan only when there is suspicion of bone metastases (a PET\u002FCT scan can substitute for the bone scan)\n* Started or planning to start platinum-based induction systemic therapy.\n* Planning to receive intensity modulated radiation therapy (IMRT) with concurrent, platinum-based systemic therapy during radiation.\n* Use of adjuvant (post-chemoradiation) immunotherapy is permitted.\n* Age \\>=18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 50%).\n* Human immunodeficiency virus (HIV)-infected individuals on effective anti-retroviral therapy are eligible for this trial.\n* For individuals with evidence of chronic hepatitis B virus (HBV) infection: must be on suppressive therapy, if indicated.\n* For individuals with a history of hepatitis C virus (HCV) infection: must be currently on treatment, or must have been treated and cured.\n* Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Because the radiation therapy used in this trial is known to be teratogenic, individuals of reproductive potential must agree to use adequate contraception (e.g., hormonal or barrier methods, abstinence) for the duration of study participation and for at least 60 days after the last administration of radiation therapy. Should a study participant or their partner become pregnant or suspect pregnancy while participating in this study, they should inform their treating physician immediately.\n* Ability to understand and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Prior systemic chemotherapy for nasopharyngeal carcinoma, other than induction chemotherapy (IT); note that prior chemotherapy for a different cancer is permitted\n* Prior radiotherapy to the nasopharynx or surrounding involved areas that would result in overlap of radiation therapy fields\n* Has participated in a study of an investigational product and received treatment with an investigational drug or used an investigational device within 4 weeks prior to the first dose of treatment\n* Severe, active comorbidity, defined as any of the following:\n\n  * Major medical or psychiatric illness that, in the treating investigator's opinion, would interfere with the completion of therapy and follow-up or interfere with a full understanding of the risks and potential complications of the therapy\n  * Unstable angina, congestive heart failure, or peripheral vascular disease requiring hospitalization within the last 12 months; or other cardiac compromise that in the judgment of the treating investigator will preclude safe administration of study treatment\n  * Chronic obstructive pulmonary disease (COPD) exacerbation or other respiratory illness requiring hospitalization within 30 days prior to registration, or which would preclude safe administration study therapy in the opinion of the treating investigator\n  * Active, untreated infection and\u002For acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\n* Because the radiation therapy used in this trial is known to be teratogenic, individuals of child-bearing potential must have documentation in their medical record of a negative pregnancy test\n\n  \\* A female participant is considered to NOT be of child-bearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if the participant meets either of the following two criteria:\n  * Has reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause)\n  * Has undergone surgical sterilization (i.e., hysterectomy and\u002For bilateral oophorectomy for removal of uterus and\u002For ovaries)\n* Individuals with any condition or social circumstance that, in the opinion of the investigator, would impair the participant's ability to comply with study activities or interfere with participant safety or study endpoints",{"count":109,"type":22},66,[111],"NA","This clinical trial tests the effect of induction chemotherapy response-guided radiation (de-escalated intensity-modulated radiation therapy \\[IMRT\\]) compared to standard IMRT in patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. Intensity-modulated radiation therapy (IMRT) is an advanced form of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Radiation therapy sometimes causes unwanted symptoms or side effects, including late effects such as hearing loss and dental problems. The severity of the side effects is related to the radiation dose received and the amount of tissue that received radiation. De-escalation IMRT uses lower doses of radiation based on a good response to induction chemotherapy. Giving de-escalated IMRT may be as effective as standard doses of IMRT in treating patients with EBV-associated nasopharyngeal cancer.",[32,114,115,116,117],"Stage III Nasopharyngeal Carcinoma AJCC v8","Stage IVA Nasopharyngeal Carcinoma AJCC v8","Nasopharyngeal Cancer","Nasopharyngeal Cancer Stage",[119,120,121],"HHV-4 Positive","EBV Positive","human herpesvirus 4 (HHV-4) positive","2026-06-15",{"date":124,"type":53},"2026-06-17",{"date":126,"type":53},"2025-03-18",{"date":128,"type":22},"2032-03-31",{"name":130,"class":101},"University of California, San Francisco",{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":140,"conditions":141,"keywords":151,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":61},"100552955","phase-1-212pbvmt-alpha-net-in-metastatic-or-inoperable-somatostatin-receptor-positive-gastrointestinal-neuroendocrine-tumors-pheochromocytomaparagangliomas-small-cell-lung-renal-cell-and-head-and-neck-cancers-100552955","NCT06479811","[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma\u002FParagangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers","Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma\u002FParagangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers","* INCLUSION CRITERIA:\n* Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma\u002Fparaganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \\& Neck cancers (nasopharyngeal carcinoma \\[NPC\\], olfactory neuroblastoma \\[ONB\\], sinonasal neuroendocrine carcinoma \\[SNEC\\]) that are metastatic or inoperable per Standard of Care. Note: for KC, all histopathologies of kidney cancers are eligible as long as it is a primary renal neoplasm.\n* Required prior therapies:\n* GI NET, PPGL, H\\&N: no specific prior therapy is needed.\n* SCLC: At least one prior line of standard of care systemic treatment such as chemotherapy and\u002For immunotherapy.\n* KC: Renal cell carcinoma (RCC) participants should have received at least one line of prior therapy in the metastatic setting and should have received at least one Programmed cell death protein 1 (PD1) \u002F Programmed death-ligand 1 (PDL1)-targeted immune checkpoint inhibitor as well as one agent targeting the VEGF pathway. Participants with fumarate hydratase (FH) deficient RCC should have received at least one prior line of systemic therapy (such as bevacizumab plus erlotinib). No prior therapy is needed for participants with other histologic subtypes.\n* Have NOT received prior systemic radioligand therapy for definitive therapeutic purposes. Prior external beam radiation therapy is allowed.\n* History of disease progression by imaging (e.g., RECIST 1.1) or clinically (defined as increase in severity or frequency of symptoms related to disease) within the past 36 months prior to the first dose of \\[203Pb\\]VMT-Alpha-NET.\n* Evidence of somatostatin receptors (SSTR) expression on at least 50% of the radiographically identifiable (i.e., visible on an anatomic scan such as CT or magnetic resonance imaging \\[MRI\\]) tumor, as indicated by a positive (uptake qualitatively identifiable as above the local background) on SSTR PET scan.\n* Age \\>= 18 years.\n* ECOG performance status \\\u003C=1.\n* Participants must have adequate organ and marrow function as defined below:\n\n  * Leukocytes: 3,000\u002Fmicroliter\n  * Absolute Neutrophil Count: 1,500\u002Fmicroliter\n  * Platelets 100,000\u002Fmicroliter\n  * Hemoglobin \\>= 9.0 g\u002FdL\n  * Total bilirubin: within normal institutional limits. Note: \\\u003C= 5 X institutional upper limit of normal (ULN) if bilirubin elevation is due to a benign process such as Gilbert syndrome\n  * AST: \\\u003C= 2.5 X institutional ULN\n  * ALT: \\\u003C= 2.5 X institutional ULN\n  * Creatinine: within normal institutional limits\n\nOR\n\n* Calculated creatinine clearance (glomerular filtration rate (eGFR): \\>= 60 mL\u002Fmin\u002F1.73 m\\^2 for participants with creatinine levels above institutional normal\n\n  * Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression at screening.\n  * Participants with new or progressive brain metastases or leptomeningeal disease are eligible as long as the participant is asymptomatic and not requiring medication for symptom control from the brain lesions at screening.\n  * Participants seropositive for human immunodeficiency virus (HIV) must:\n* be on effective anti-retroviral therapy; and\n* have an undetectable viral load at screening.\n\n  * Participants seropositive for hepatitis B virus (HBV), must have HBV viral load undetectable at screening.\n  * Participants seropositive for hepatitis C virus (HCV) must:\n* received curative treatment; and\n* have an undetectable HCV viral load at screening.\n\n  * Individuals of child-bearing potential (IOCBP) and individuals who can father children must agree to use an effective method of contraception (barrier, hormonal, intrauterine device \\[IUD\\], surgical sterilization, abstinence) at study entry and up to 6 months after the last dose of the study agent(s).\n  * Nursing participants must be willing to discontinue nursing from study treatment initiation through 6 months after the last dose of the study agents.\n  * The ability of the participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Any investigational agents should be stopped at least 28 days prior to the first dose of \\[203Pb\\]VMT-Alpha-NET.\n* Systemic therapy should be stopped at least 28 days prior to the first dose of \\[203Pb\\]VMT-Alpha-NET (participants with prior systemic therapies for their malignancy only, except participants with SCLC).\n* Systemic therapy should be stopped at least 14 days prior to the first dose of \\[203Pb\\]VMT-Alpha-NET (participants with SCLC only).\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to VMT-Alpha-NET.\n* Positive Beta human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test performed in IOCBP at screening.\n* QTc \\> 450 ms on electrocardiogram (EKG) at screening. Note: Framingham correction for QTc will be used\n* History of or detection at screening of active\u002Funtreated secondary malignancy except nonmelanoma skin cancer and carcinoma in situ of the uterine cervix.\n* Uncontrolled intercurrent illness, factors, evaluated by medical history and physical exam which would potentially increase in the risk of the participant.",{"count":21,"type":22},[25],"Background:\n\nSome cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Researchers want to know if drug treatments that target SSTRs can help shrink these types of tumors.\n\nObjective:\n\nTo test a study drug (\\[212Pb\\]VMT-Alpha-NET) in people with tumors that have SSTRs.\n\nEligibility:\n\nPeople aged 18 years and older with tumors of the lung, kidneys, head and neck, digestive tract, or adrenal glands that have SSTRs. Their tumors must have spread to other organs and cannot be removed with surgery.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood and urine tests. They will have imaging scans and a test of their heart function. A sample of tumor tissue may be collected if one is not already available.\n\n\\[212Pb\\]VMT-Alpha-NET is given through a tube attached to a needle inserted into a vein. The drug will be given on the first day of four 8-week cycles. Participants will stay in the hospital for a few nights after each dose. They will have blood tests once a week during each cycle.\n\nSome participants will also get a related study drug (\\[203Pb\\]VMT-Alpha-NET). They will receive this drug a few days before the first 2 cycles. At 4, 24, and 48 hours after each infusion, they will have whole body scans. These scans will show where the study drug went in their body.\n\nFollow-up visits will continue up to 6 years after the last treatment.",[142,32,143,144,145,146,147,148,149,150],"Sinonasal Neuroendocrine Carcinoma","Esthesioneuroblastoma","Olfactory Neuroblastoma","Somatostatin Receptor Positive","Small Cell Lung Cancers","Pheochromocytoma\u002FParagangliomas","Kidney Cancers","Head and Neck Tumors","Gastrointestinal Neuroendocrine Tumors",[152,153,154,155],"212Pb","Targeted alpha Therapy","Image-Guided Dosimetry","VMT-alpha-NET","2026-06-11",{"date":158,"type":53},"2026-06-12",{"date":160,"type":53},"2025-08-19",{"date":162,"type":22},"2032-01-01",{"name":59,"class":60},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},"100642704","phase-1-a-study-of-cemiplimab-and-fianlimab-in-people-with-nasopharyngeal-carcinoma-100642704","NCT07650266","A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma","A Pilot Randomized Trial of Induction Cemiplimab With or Without Fianlimab in De-escalated Chemoradiation for Locoregionally Advanced Non-Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Age ≥ 18\n* Pathologically (histologically or cytologically) proven (from primary lesion and\u002For lymph node) diagnosis of non-keratinizing nasopharynx carcinoma\n* Pathologic confirmation of EBV status in biopsy sample. EBER (Epstein-Barr virus-encoded RNA) detection via immunohistochemistry or in situ hybridization or polymerase chain reaction, collected as routine clinical standard to determine EBV status.\n* Patient must be seen by head and neck surgery, radiation oncology, medical oncology, as standard of care which includes standard nasopharyngoscopy. All three disciplines need to agree that the patient is eligible. Note: Nasopharyngoscopy does not need to be repeated by all three disciplines. This test is often only performed by head and neck surgery and\u002For radiation oncology.\n* AJCC 8th edition: T1N1, T2N0-1, T1-T2N2 nasopharynx carcinoma\n* ECOG performance status 0-1\n* Adequate organ and bone marrow function documented by:\n\n  * Hemoglobin \\> 9.0 g\u002FdL\n  * Absolute neutrophil count (ANC) \\>1.5 x 109 \u002FL\n  * Platelet count \\>100 x 109 \u002FL\n  * Adequate renal function: Serum creatinine \\\u003C1.5 mg\u002FdL or creatinine clearance ≥ 50 ml\u002Fmin determined by 24-hour urine collection or estimated by Cockcroft-Gault formula\n  * Adequate hepatic function: - T bili \\\u003C1.5x ULN, AST or ALT \\\u003C 1.5 ULN, Alkaline phosphatase \\\u003C1.5 x ULN). Note: for patients with Gilbert Syndrome, total Bilirubin \\\u003C3x ULN.\n* Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential\n* Signed informed consent form by the participant.\n\nExclusion Criteria:\n\n\\- Evidence of distant metastatic disease by radiographic imaging. Equivocal findings are subject to P.I. and Co-PI approval\n\n* Prior head and neck radiation (Exceptions can be made if the overlap regions are minimal and must be approved by PI\u002FCo-PI)\n* Grade ≥2 hearing loss\n* Grade ≥2 peripheral sensory neuropathy\n* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate from treatment at 5 years is 90% or greater\n\n  o Note: Exceptions can be made for patients with prior or concurrent invasive malignancy if determined by the PI\u002FCo-PI, then the patient can proceed with protocol activities\n* Prior systemic chemotherapy for the study cancer o Note: prior chemotherapy for a different cancer is allowable, must check with PI\u002FCo-PI\n* Severe, active co-morbidity defined as follows:\n\n  o Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months\n  * Transmural myocardial infarction within the last 6 months\n  * Acute bacterial or fungal infection requiring intravenous antibiotics treatment within 2 weeks prior to the first dose of trial medication\n  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within 30 days of registration\n  * Hepatic insufficiency resulting in clinical jaundice and\u002For coagulation defects\n* Lack of ability to understand and willingness to sign a written informed consent and complete questionnaires.\n* Participants with a history of myocarditis.\n* TnT or troponin I TnI \\> 2x institutional ULN at baseline. Patients with TnT or TnI levels between \\> 1 to 2x ULN are permitted if repeat levels within 24 hours are ≤ 1x ULN. If TnT or TnI levels are \\> 1 to 2x ULN within 24 hours, the patient may undergo a cardiac evaluation and be considered for treatment by the investigator based on the medical judgement in the patient's best interest.\n* History or current evidence of significant (CTCAE grade ≥2) local or systemic infection (eg, cellulitis, pneumonia, septicemia) requiring systemic antibiotic treatment within 2 weeks prior to the first dose of trial medication.\n* Uncontrolled infection with HIV, HBV, or HCV infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection.\n\n  o Patients with known HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are permitted. For patients with controlled HIV infection, monitoring will be performed per local standards.\n  * Patients with known hepatitis B (HepBsAg+) who have controlled infection (serum hepatitis B virus DNA PCR that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA per local standards and must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study drug.\n  * Patients who are known hepatitis C virus antibody positive (HCV Ab+) who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are permitted.\n* Patients with HIV or hepatitis must be reviewed by a qualified specialist (e.g., infectious disease or hepatologist) managing this disease prior to commencing and regularly throughout the duration of their participation in the trial\n* Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents. The following are non-exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement, psoriasis not requiring systemic treatment.\n* Known hypersensitivity to the active substances or to any of the excipients.\n* Patients using immunosuppressive doses (≥10 mg per day of prednisone or equivalent) of systemic corticosteroids other than for corticosteroid replacement will not be eligible for the study.\n* Received a live vaccine within 30 days of planned start of study medication, during treatment and for 90 days after treatment.\n\n  o Live or live attenuated vaccination with replicating potential. If a patient intends to receive a COVID-19 vaccine before the start of study drug, participation in the study should be delayed at least 1 week after any COVID-19 vaccination. During the treatment period, it is recommended to delay COVID-19vaccination until patients are receiving and tolerating a steady dose of study drug. A vaccine dose should not be less than 48 hours before or after study drug dosing.\n* Woman of child bearing potential (WOCBP)\\* must have a negative serum (beta-hCG) within 14 days prior to registration.\n\n  * \\*WOCBP are defined as women who are fertile following menarche until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.\n  * Pregnancy testing and contraception are not required for women who are post-menopausal or permanently sterile.\n  * A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to determine the occurrence of a postmenopausal state. The above definitions are according to the CTFG guidance. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation\n  * Male study participants with WOCBP partners are required to use condoms during the study and until 6 months after the last dose of study treatment unless they are vasectomized or practice sexual abstinence†\n  * Vasectomized partner or vasectomized study participant must have received medical assessment of the surgical success.\n  * Periodic abstinence‡, withdrawal (coitus interruptus), spermicides only, and LAM are not acceptable methods of contraception. Female condom and male condom should not be used together.\n* WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire trial and until 6 months after last treatment\n* All men must agree not to donate sperm during the trial and for 6 months after receiving the last therapy dose\n* Pregnant or breastfeeding women. o WOCBP who are unwilling to practice highly effective contraception prior to the initial dose\u002Fstart of the first treatment, during the study, and for at least 6 months after the last dose. Highly effective contraceptive measures include: i. stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening; ii. intrauterine device; intrauterine hormone-releasing system; iii. bilateral tubal occlusion\u002Fligation; iv. vasectomized partner (provided that the male vasectomized partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has obtained medical assessment of surgical success for the procedure); and\u002For v. sexual abstinence† ‡\n\n  * Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drugs. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.\n\n    * Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and LAM are not acceptable methods of contraception. Female condom and male condom should not be used together.",{"count":172,"type":22},60,[25],"The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.",[32,116,176,177],"Nasopharynx Carcinoma","Nasopharynx Cancer",[32,116,176,177,179,180,181],"Locoregionally Advanced Non-Metastatic Nasopharyngeal Carcinoma","Memorial Sloan Kettering Cancer Center","26-172","2026-06-10",{"date":184,"type":53},"2026-06-16",{"date":186,"type":22},"2026-07",{"date":188,"type":22},"2030-07",{"name":180,"class":101},7,{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":216},"100537378","phase-3-maintenance-therapy-with-toripalimab-and-capecitabine-versus-capecitabine-alone-in-high-risk-nasopharyngeal-carcinoma-100537378","NCT06277050","Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma","Maintenance Therapy With Toripalimab Combined With Capecitabine Versus Maintenancetherapy With Capecitabine Alone in High-risk Nasopharyngeal Carcinoma: a Multicenter, Prospective, Randomized Phase III Clinical Trial (NPC-ICMB)","Inclusion Criteria:\n\n1. Pathologically confirmed nasopharyngeal carcinoma;\n2. High-risk nasopharyngeal cancer meets one of three points: a. TanyN3M0; b. High-grade rENE, coalescent nodal or invasion of surrounding structures (muscle, skin, nerves, etc.); c. Detectable EBV DNA after 2 cycles of induction chemotherapy.\n\n3.18-70 years old, both genders; 4. ECOG≤1; 5. Received 2-3 cycles of induction chemotherapy and concurrent chemoradiotherapy (intensity-modulated radiotherapy); 6. Patients must have adequate organ function (without blood transfusion, without growth factor or blood components support within 14 days before enrollment) as determined by: Absolute neutrophil count (ANC) ≥1.5×109\u002FL; Platelet count ≥ 75×109\u002FL; Hemoglobin ≥ 9 g\u002FdL; serum total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×upper limit of normal (ULN), (for subjects with liver metastases, TBIL ≤3×ULN; ALT and AST≤5×ULN); Creatinine ≤1.5×ULN or creatinine clearance rate≥50 ml\u002Fmin (Cockcroft-Gault formula); serum albumin ≥28 g\u002FL.\n\n7\\. All women with fertility potential must undergo a urine or serum pregnancy test during screening and the results are negative; 8. Written informed consent;\n\nExclusion Criteria:\n\n1. Recurrent or distant metastatic nasopharyngeal carcinoma.\n2. History of malignant tumors (except cured basal cell carcinoma or uterine cervical carcinoma in situ) within the last 5 years.\n3. Has received any prior radiotherapy (RT) or systemic anti-cancer therapy including investigational agents for NPC\n4. Has received prior therapy with an anti-PD-1 mab.\n5. Active autoimmune diseases or history of autoimmune diseases that may relapse.\n\n   Note: Patients with the following diseases are not excluded and may proceed to further screening:\n   1. Controlled Type I diabetes\n   2. Hypothyroidism (provided it is managed with hormone replacement therapy only)\n   3. Controlled celiac disease\n   4. Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia) Any other disease that is not expected to recur in the absence of external triggering factors.\n6. Any condition that required systemic treatment with either corticosteroids (\\>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤14 days before the start of the study。\n\n   Note: Patients who are currently or have previously been on any of the following steroid regimens are not excluded:\n   1. Adrenal replacement steroid (dose ≤10 mg daily of prednisone or equivalent)\n   2. Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption\n   3. Short course (≤7 days) of corticosteroid prescribed prophylactically (e.g., for contrast dye allergy) or for the treatment of a non-autoimmune condition (e.g., delayed-type hypersensitivity reaction caused by contact allergen)。\n7. With history of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.\n8. With severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, etc.\n\n   1. Severe infections within 4 weeks before the start of the study, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.\n   2. Received therapeutic oral or intravenous antibiotics within 2 weeks before start of the study.\n9. A known history of HIV infection\n10. Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers whose HBV DNA is \\>1000 IU\u002FmL or patients with active hepatitis C virus (HCV) should be excluded. Note: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA \\\u003C1000 IU\u002FmL), and cured hepatitis C patients can be enrolled.\n11. Any major surgical procedure requiring general anaesthesia ≤28 days before start of study。\n12. Prior allogeneic stem cell transplantation or organ transplantation.\n13. Any of the following cardiovascular risk factors:\n\n    1. Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily living, ≤28 days before start of study\n    2. Pulmonary embolism ≤28 days before start of study\n    3. Any history of acute myocardial infarction ≤6 months before start of study\n    4. Any history of heart failure meeting New York Heart Association (NYHA) Classification III or IV ≤6 months before start of study\n    5. Any event of ventricular arrhythmia ≥Grade 2 in severity ≤6 months before start of study\n    6. Any history of cerebrovascular accident ≤6 months before start of study\n    7. Uncontrolled hypertension: systolic pressure ≥160 mmHg or diastolic pressure ≥100 mmHg despite anti-hypertension medications ≤28 days before start of study\n    8. Any episode of syncope or seizure ≤28 days before start of study.\n14. A history of severe hypersensitivity reactions to toripalimab, capecitabine and\u002For any of its excipients.\n15. Has received any herbal medicine used to control cancer within 14 days of the start of study\n16. Patients with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized, except for AEs not considered a likely safety risk (e.g., alopecia, neuropathy and specific laboratory abnormalities)\n17. Concurrent participation in another therapeutic clinical study\n18. Emotional disturbance or mental illness\n19. Refusal or inability to sign informed consent","70 Years",{"count":200,"type":22},264,[202],"PHASE3","N3 classification, rENE positivity is a high-risk type of locally advanced nasopharyngeal carcinoma. EBV DNA remaining at detectable levels after induction chemotherapy is also a characteristic of high-risk nasopharyngeal carcinoma. Based on the available evidence, patients with high-risk nasopharyngeal carcinoma are recommended to receive oral maintenance therapy to reduce the risk of failure.\n\nThe purpose of this study was to conduct a prospective, multicenter, randomized phase III clinical trial to determine whether maintenance therapy with triprilimab combined with capecitabine is better than maintenance therapy with capecitabine alone in high-risk nasopharyngeal carcinoma (N3+, rENE+, Detectable EBV DNA after 2 cycles of induction chemotherapy).",[32,205,206],"High-Risk Cancer","Maintenance Therapy","2026-05-13",{"date":209,"type":53},"2026-05-15",{"date":211,"type":53},"2024-03-07",{"date":213,"type":22},"2031-02-20",{"name":215,"class":101},"Jiangxi Provincial Cancer Hospital",3,{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":17,"minAge":225,"maxAge":18,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":61},"100641039","phase-1-phase-i-study-of-becotatug-vedotin-for-safety-and-efficacy-in-egfr-positive-pediatric-relapsedrefractory-or-metastatic-solid-tumors-100641039","NCT07584499","Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed\u002FRefractory or Metastatic Solid Tumors","A Phase I Clinical Study to Explore the Safety and Efficacy of Becotatug Vedotin in Pediatric Patients With EGFR-Positive Relapsed\u002FRefractory or Metastatic Solid Tumors","MRG003","Inclusion Criteria:\n\n* All participants must meet all of the following criteria to be eligible for enrollment:\n\nInformed Consent: The patient (and\u002For legal guardian, as age-appropriate) fully understands the study, voluntarily agrees to participate, and signs a written informed consent form (ICF). A separate biomarker consent form is required for EGFR testing prior to screening.\n\nAge: 2 to 18 years old at the time of consent. Life Expectancy: Estimated overall survival of at least 3 months.\n\nHistologically Confirmed Disease: Pathologically confirmed relapsed\u002Frefractory or metastatic EGFR-positive solid tumor, belonging to one of the following subtypes:\n\nHead and neck squamous cell carcinoma, nasopharyngeal carcinoma, or lymphoepithelial carcinoma that progressed during or after at least one line of platinum-based chemotherapy and PD-1\u002FPD-L1 inhibitor therapy Rhabdomyosarcoma Neuroblastoma Medulloblastoma Wilms tumor Atypical teratoid\u002Frhabdoid tumors (AT\u002FRTs) Diffuse intrinsic pontine gliomas (DIPGs) Other EGFR-positive solid tumor subtypes deemed eligible by the investigator Measurable Disease: At least one measurable tumor lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria (longest diameter ≥10 mm; pathological lymph node short axis ≥15 mm).\n\nPerformance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.\n\nAdequate Bone Marrow Function:\n\nAbsolute neutrophil count (ANC) ≥1.5 × 10⁹\u002FL Platelet count ≥75 × 10⁹\u002FL Hemoglobin ≥80 g\u002FL Exception for patients with bone marrow involvement: ANC ≥1.0 × 10⁹\u002FL, platelets ≥50 × 10⁹\u002FL, hemoglobin ≥75 g\u002FL\n\nAdequate Hepatic and Renal Function:\n\nSerum creatinine ≤1.5 × upper limit of normal (ULN) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN Total bilirubin ≤1.5 × ULN Exception for patients with liver involvement: AST\u002FALT ≤5 × ULN, total bilirubin ≤3 × ULN\n\nExclusion Criteria:\n\n* Participants will be excluded from the study if they meet any of the following criteria:\n\nHypersensitivity: Known hypersensitivity to any component of Becotatug Vedotin (MRG003) or its excipients.\n\nSymptomatic CNS Metastases: Presence of symptomatic central nervous system (CNS) metastases.\n\nPrior Malignancies: History of other primary malignant tumors, except for:\n\nLocally excised basal cell or squamous cell carcinoma of the skin Cervical carcinoma in situ Any prior malignancy that has been in complete remission for ≥3 years without treatment Note: Melanoma (any stage) is explicitly excluded\n\nSignificant Liver Disease: Clinically significant liver disease, including:\n\nPositive hepatitis C virus (HCV) antibody Chronic active hepatitis B (HBV DNA \\>20,000 IU\u002FmL) HIV Infection: Known human immunodeficiency virus (HIV) infection. Severe Ocular Abnormalities: History of severe ophthalmologic conditions, such as severe dry eye syndrome or exposure keratitis.\n\nUncontrolled Systemic Diseases: Severe or uncontrolled medical conditions, including:\n\nInterstitial lung disease or pneumonitis Active autoimmune diseases requiring systemic immunosuppressive therapy\n\nCardiac Disease: Clinically significant cardiac dysfunction or cardiac disease, including:\n\nCongestive heart failure (New York Heart Association Class ≥II) Uncontrolled arrhythmias QTc interval prolongation \\>450 ms (males) or \\>470 ms (females) Recent Antitumor Therapy: Received any systemic antitumor therapy (chemotherapy, biological therapy, immunotherapy, targeted therapy) within 3 weeks prior to the first dose of study drug, and have not recovered to CTCAE v4.03 Grade ≤1 (except alopecia).\n\nRecent Major Surgery: Underwent major surgical procedure within 3 weeks prior to the first dose of study drug.\n\nPlanned Surgery: Planned surgical procedure during the study period, or any surgery deemed necessary by the investigator.\n\nPrior EGFR Therapy Toxicity: History of severe skin toxicity caused by prior EGFR-targeted therapy, or chronic skin disease requiring ongoing oral or intravenous treatment.\n\nOther Significant Risks: Any other concurrent medical condition that, in the investigator's judgment, would increase the risk of toxicity or compromise the patient's ability to complete the study.","2 Years",{"count":227,"type":22},51,[25],"There is a significant unmet medical need for effective therapies for pediatric relapsed\u002Frefractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug Vedotin demonstrated a manageable safety profile and promising antitumor activity in EGFR-positive advanced solid tumors.This is a multicenter, non-randomized, single-arm, open-label Phase I clinical trial sponsored by Sun Yat-sen University Cancer Center (SYSUCC). The trial evaluates the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary efficacy of Becotatug Vedotin-an EGFR-targeted antibody-drug conjugate (ADC)-in pediatric patients with EGFR-positive relapsed\u002Frefractory or metastatic solid tumors.",[231,32,232,233,234,235,236,237,238,239],"Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent\u002FMetastatic (R\u002FM)","Lymphoepithelial Carcinoma","Rhabdomyosarcoma","Neuroblastoma","Medulloblastoma","Wilms Tumor","Atypical Teratoid\u002FRhabdoid Tumors","Diffuse Intrinsic Pontine Gliomas","Other EGFR-positive Pediatric Solid Tumors Deemed Eligible by the Investigator","2026-05-07",{"date":207,"type":53},{"date":243,"type":22},"2026-05-30",{"date":245,"type":22},"2028-05-30",{"name":247,"class":101},"Sun Yat-sen University",{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":267,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":61},"100581617","phase-2-cd70-targeted-immunopet-imaging-of-malignant-cancers-100581617","NCT06852638","CD70-targeted immunoPET Imaging of Malignant Cancers","CD70-targeted PET\u002F CT in the Diagnosis of Malignant Cancers","Inclusion Criteria:\n\n* Aged 18-80 year-old and of either sex；\n* Histologically confirmed diagnosis of renal cancer (especially ccRCC)\u002Flymphoma\u002FNPC or suspected renal cancer\u002Flymphoma\u002FNPC by diagnostic imaging;\n* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n* Pregnancy；\n* Severe hepatic and renal insufficiency;\n* Allergic to single-domain antibody radiopharmaceuticals.","80 Years",{"count":257,"type":22},300,[26],"This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography\u002Fcomputed tomography (immunoPET\u002FCT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.",[261,262,263,264,265,266,32],"Renal Cancer","Renal Clear Cell Carcinoma","Lymphoma","Lymphoma, Large B-Cell, Diffuse","Follicular Lymphoma","Mantle Cell Lymphoma",[268,269,261,263,32],"The cluster of differentiation (CD70)","ImmunoPET",{"date":271,"type":53},"2026-05-12",{"date":273,"type":53},"2024-12-23",{"date":275,"type":22},"2026-12-23",{"name":277,"class":101},"RenJi Hospital",{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":288,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":61},"100540929","phase-2-sbrt-and-ldrt-combined-with-pd-1-antibody-and-chemotherapy-in-rm-nasopharyngeal-carcinoma-100540929","NCT06323239","SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r\u002Fm Nasopharyngeal Carcinoma","Stereotactic Body Radiotherapy (SBRT) and Low-dose Radiotherapy (LDRT) Combined With Programmed Death 1 (PD-1) Antibody and Chemotherapy in Recurrent\u002FMetastatic Nasopharyngeal Carcinoma: A Prospective, Single-arm, Phase II Clinical Trial","Inclusion Criteria:\n\n* Diagnosed as recurrence\u002Fmetastatic NPC\n* Histopathological diagnosis of NPC(WHO II\u002FIII)\n* ECOG 0-1 point\n* No treatment to r\u002FmNPC, such as radiotherapy, chemotherapy, immunotherapy or biotherapy;\n* No contraindications to immunotherapy and chemoradiotherapy;\n* At least one lesion could receive SBRT safely;\n* Subject must have a measurable target lesion based on RECIST v1.1;\n* Adequate marrow function: WBC count ≥ 3×10E9\u002FL, NE count ≥ 1.5×10E9\u002F L, HGB ≥ 90g\u002FL, PLT count ≥ 100×10E9\u002FL;\n* Adequate liver function: ALT\u002FAST ≤ 2.5×ULN, TBIL ≤ 2.0×ULN;\n* Adequate renal function: BUN\u002FCRE ≤ 1.5×ULN or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* Take effective contraceptions during and three months after treatment;\n* Patients must be informed of the investigational nature of this study and give written informed consent.\n\nExclusion Criteria:\n\n* Allergic to monoclonal antibodies, any PD-1 antibody components, gemcitabine and cisplatin;\n* Unexplained fever \\> 38.5 #, except for tumor fever;\n* Have active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy);\n* Have a known history of human immunodeficiency virus (HIV), active Hepatitis B (HBV-DNA ≥10E3copiers\u002Fml) or hepatitis C virus (HCV) antibody positive;\n* Have New York Heart Association (NYHA) class 3 or 4, unstable angina, myocardial -infarction within 1 year, or clinically meaningful arrhythmia that requires treatment; Have known allergy to large molecule protein products or any compound of study therapy;\n* Pregnant or breastfeeding;\n* Prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, and papillary thyroid carcinoma;\n* Have received a live vaccine within 30 days of planned start of study therapy Has psychiatric drug or substance abuse disorders that would interfere with cooperation with the requirements of the trial;\n* Any other condition, including mental illness or domestic\u002Fsocial factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results.","75 Years",{"count":287,"type":22},148,[26],"This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent\u002Fmetastatic nasopharyngeal carcinoma patients.",[32],[292,293,294,44],"SBRT","Low-dose radiotherapy","PD-1 antibody","2026-05-06",{"date":297,"type":53},"2026-05-11",{"date":299,"type":53},"2024-07-15",{"date":301,"type":22},"2028-12",{"name":247,"class":101},{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":310,"targetDuration":4,"studyType":312,"phases":4,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":320,"leadSponsor":321,"locationsCount":61},"100531282","investigation-of-multi-omics-technique-to-predict-the-efficacy-of-chemoradiotherapy-combined-with-immunotherapy-for-rm-npc-100531282","NCT06197776","Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r\u002Fm NPC","Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for Recurrent and\u002For Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Recurrent or metastatic nasopharyngeal carcinoma patients\n* All genders，range from 18～70 years old\n* ECOG score 0 \\~ 1\n* Inform consent form\n\nExclusion Criteria:\n\n* Have or are suffering from other malignant tumors;\n* Participating in other clinical trials;\n* Drug or alcohol addition;\n* Do not have full capacity for civil acts;\n* Mental disorder;\n* Pregnancy or lactation;\n* Severe complication, eg, uncontrolled hypertension.",{"count":311,"type":22},50,"OBSERVATIONAL","The observational clinical study will recruit 50 recurrent and\u002For metastatic nasopharyngeal carcinoma (r\u002FmNPC) patients, to investigate the prediction values of multi-omics technique for the efficacy of chemoradiotherapy combined with immunotherapy.",[315,32,316,317],"Multi-omics Technique","Recurrent and Metastatic Nasopharyngeal Carcinoma","Efficacy of Chemoradiotherapy and Immunotherapy",{"date":297,"type":53},{"date":299,"type":53},{"date":301,"type":22},{"name":247,"class":101},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":329,"targetDuration":4,"studyType":23,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":216},"100511615","phase-3-ic-plus-low-dose-radiation-plus-cadonilimab-in-lanpc-100511615","NCT05941741","IC Plus Low-dose Radiation Plus Cadonilimab in LANPC","Induction Chemotherapy Combined With Low-dose Radiation Plus Cadonilimab in Loco-regionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Open-label, Randomized Controlled Phase III Clinical Trial","Inclusion Criteria:\n\n* Newly histologic diagnosis of nasopharyngeal non-keratinizing carcinoma (WHO II\u002FIII);\n* All genders, range from 18-70 years old;\n* ECOG score 0-1;\n* Clinical stage T4N1M0 and T1-4N2-3M0 (AJCC\u002FUICC 8th);\n* Not received radiotherapy, chemotherapy and other anti-tumor treatment (including immunotherapy);\n* No contraindications to chemotherapy, radiotherapy or immunotherapy;\n* Adequate organ function: white blood cell count ≥ 4×109\u002FL, neutrophile granulocyte count ≥ 1.5×109\u002FL, hemoglobin ≥ 9g\u002FL, platelet count ≥ 100×109\u002FL; alanine aminotransferase or aspartate aminotransferase \\\u003C 2.5×upper limit of normal; blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* Sign the consent form.\n\nExclusion Criteria:\n\n* Distant metastases;\n* Keratinized squamous cell carcinoma or basal cell like squamous cell carcinoma;\n* Have or are suffering from other malignant tumors;\n* Participating in other clinical trials;\n* Pregnancy or lactation;\n* Have uncontrolled cardiovascular disease;\n* Severe complication, eg, uncontrolled hypertension;\n* Mental disorder;\n* Drug or alcohol addition;\n* Do not have full capacity for civil acts.",{"count":330,"type":22},380,[202],"This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.",[32,334,335,44],"Immune Checkpoint Inhibitor","Radiotherapy",{"date":297,"type":53},{"date":338,"type":53},"2024-01-10",{"date":340,"type":22},"2029-12",{"name":247,"class":101},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":352,"conditions":353,"keywords":354,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":365},"100465420","phase-3-chemoradiotherapy-plus-anti-pd1-in-recurrent-npc-a-multicenter-open-label-randomised-controlled-phase-iii-trial-100465420","NCT05340491","Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial","Chemoradiotherapy Combined With Programmed Death 1 Antibody in Recurrent Nasopharyngeal Carcinoma: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial","Inclusion Criteria:\n\n* Diagnosed as local with or without regional recurrence after ≥1 year of radical treatment;\n* Not suitable for surgery;\n* Histologic diagnosis of NPC (WHO II\u002FIII);\n* TNM stage rII-IVa (AJCC\u002FUICC 8th);\n* ECOG 0-1 point;\n* No treatment to rNPC prior, such as radiotherapy, chemotherapy, immunotherapy or biotherapy;\n* No contraindications to immunotherapy or chemoradiotherapy;\n* Adequate marrow function: WBC count ≥ 3×10E9\u002FL, NE count ≥ 1.5×10E9\u002FL, HGB ≥ 90g\u002FL, PLT count ≥ 100×10E9\u002FL;\n* Adequate liver function: ALT\u002FAST ≤ 2.5×ULN, TBIL ≤ 2.0×ULN;\n* Adequate renal function: BUN\u002FCRE ≤ 1.5×ULN or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* Take effective contraceptions during and two months after treatment;\n* Patients must be informed of the investigational nature of this study and give written informed consent.\n\nExclusion Criteria:\n\n* Treated with anti-tumor Chinese medicine treatment;\n* Have recurrence with local necrosis;\n* Have ≥G3 late toxicities, except for skin, subcutaneous tissue or mucosa;\n* Unexplained fever \\> 38.5, except for tumor fever;\n* Treated with ≥ 5 days antibiotics one month before enrollment;\n* Have active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy); Have a known history of human immunodeficiency virus (HIV), active Hepatitis B (HBV-DNA ≥10E3copiers\u002Fml) or hepatitis C virus (HCV) antibody positive; Have previously treated with PD-1 antibody or other immunotherapy for PD-1\u002FPD-L1 pathway;\n* Have New York Heart Association (NYHA) class 3 or 4, unstable angina, myocardial -infarction within 1 year, or clinically meaningful arrhythmia that requires treatment;\n* Have known allergy to large molecule protein products or any compound of study therapy;\n* Pregnant or breastfeeding;\n* Prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, and papillary thyroid carcinoma;\n* Have received a live vaccine within 30 days of planned start of study therapy Has psychiatric drug or substance abuse disorders that would interfere with cooperation with the requirements of the trial;\n* Any other condition, including mental illness or domestic\u002Fsocial factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results.",{"count":350,"type":22},212,[202],"This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.",[32],[355,356,357,294,358,359],"locoregional relapse","nasopharyngeal carcinoma","chemoradiotherapy","efficacy","toxicity",{"date":297,"type":53},{"date":362,"type":53},"2022-04-01",{"date":301,"type":22},{"name":247,"class":101},12,{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":23,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":384,"locationsCount":61},"100396043","phase-3-effect-of-standard-nutrition-therapy-on-nutritional-status-and-prognosis-in-locoregionally-advanced-nasopharyngeal-carcinoma-patients-with-malnutrition-100396043","NCT04436965","Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition","Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition: A Prospective, Multicenter, Phase III Randomized Control Clinical Trial","Inclusion Criteria:\n\n* Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II\u002FIII);\n* All genders，range from 18～65 years old;\n* Karnofsky performance status(KPS) ≥ 80;\n* Clinical stage III\\~IVa(AJCC\u002FUICC 8th);\n* Without significant digestive system disease，nutritional and metabolic diseases or endocrine disease\n* Without significant cardiac，respiratory，kidney or liver disease;\n* Not received radiotherapy, chemotherapy and other anti-tumor treatment(including immunotherapy);\n* White blood cell(WBC) count ≥ 4×109\u002FL, neutrophile granulocyte(NE) count ≥ 1.5×109\u002FL, Hemoglobin(HGB) ≥ 9g\u002FL, platelet(PLT) count ≥ 100×109\u002FL\n* Total bilirubin(TBIL)、alanine aminotransferase (ALT) or aspartate aminotransferase(AST) \\\u003C 2.5×upper limit of normal(ULN);\n* Adequate renal function: BUN\u002FCRE ≤ 1.5×ULN or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* No contraindications to chemotherapy or radiotherapy;\n* Inform consent form;\n\nExclusion Criteria:\n\n* Have some PEG\u002FPEJ contraindications, such as coagulopathy, recent anticoagulant medications and aspirin, gastric ulcer or history of gastric bleeding, portal hypertension combined with abdominal and esophageal fundal varices, pyloric obstruction due to residual stomach under the costal arch after various major gastrectomy or various reasons;\n* Distance metastases;\n* Have or are suffering from other malignant tumors;\n* Participating in other clinical trials;\n* Drug or alcohol addition;\n* Do not have full capacity for civil acts;\n* Mental disorder;\n* Pregnancy or lactation;\n* Severe complication, eg, uncontrolled hypertension;","65 Years",{"count":375,"type":22},266,[202],"This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy of standard nutrition treatment versus conventional nutrition treatment in local advanced nasopharyngeal carcinoma patients.",[32,379],"Nutrition Therapy",{"date":297,"type":53},{"date":382,"type":53},"2021-08-16",{"date":340,"type":22},{"name":247,"class":101},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":404,"locationsCount":61},"100552608","phase-2-a-study-of-bl-b01d1pd-1-monoclonal-antibody-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nasopharyngeal-carcinoma-and-other-solid-tumors-100552608","NCT06475300","A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors","A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors","Inclusion Criteria:\n\n1. Sign the informed consent form voluntarily and follow the protocol requirements;\n2. Any gender;\n3. Age: ≥18 years old;\n4. Expected survival time for 3 months or more;\n5. Patients with locally advanced or metastatic non-small cell lung cancer or nasopharyngeal carcinoma confirmed by histopathology and\u002For cytology;\n6. Subjects were able to provide 6-10 slides of archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 2 years;\n7. At least one measurable lesion meeting the RECIST v1.1 definition was required;\n8. ECOG 0 or 1;\n9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;\n10. No serious cardiac dysfunction, left ventricular ejection fraction 50% or higher;\n11. screening period not allowed within 14 days before a blood transfusion, are not allowed to use any cell growth factor, and\u002For liters of platelet medicine, organ function level must conform to the requirements;\n12. Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN;\n13. The urine protein + 2 or 1000 mg \u002F 24 h or less or less;\n14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum or urine must be negative for pregnancy, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.\n\nExclusion Criteria:\n\n1. Stage 1 EGFR-sensitive mutant non-small cell lung cancer patients with systemic chemotherapy; Stage 2 patients who had received previous systemic therapy;\n2. In the second stage queue one signed informed consent before gene sequencing report suggests patients such as mutation of ALK fusion;\n3. Anti-tumor therapy such as chemotherapy or biological therapy has been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Fluorouracil class oral drugs, etc.;\n4. Serious heart disease;\n5. Long QT, complete left bundle branch block, III degree atrioventricular block; Serious arrhythmia;\n6. Active autoimmune and inflammatory diseases;\n7. Before the first delivery within 5 years diagnosed as other malignant tumor;\n8. Two antihypertensive drugs poorly controlled hypertension;\n9. Patients with poor glycemic control;\n10. With a history of ILD, current ILD or suspected suffering from such diseases during screening;\n11. Complicated with pulmonary diseases leading to severe respiratory function impairment;\n12. There is a lot of serous cavity effusion, or have a serous cavity effusion and has symptoms, or poorly controlled serous cavity effusion patients;\n13. Imaging studies suggest tumor has violated or package around the chest, neck, pharyngeal large blood vessels;\n14. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;\n15. Active central nervous system of patients;\n16. For restructuring or human mouse chimeric antibody on study of humanized anti-platelet antibody has a history of allergies or allergic to BL - B01D1 any supplementary material composition of patients;\n17. Before transplant or allogeneic hematopoietic stem cell transplantation (Allo - HSCT);\n18. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or active hepatitis C virus infection;\n19. Active infection requiring systemic therapy;\n20. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;\n21. Had participated in another clinical trial within 4 weeks before the first dose;\n22. Other conditions for trial participation were not considered appropriate by the investigator.",{"count":393,"type":22},570,[26],"This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 Monoclonal Antibody in patients with locally advanced or metastatic non-small cell lung cancer, nasopharyngeal carcinoma and other solid tumors.",[397,32,398],"Non-small Cell Lung Cancer","Solid Tumor","2026-04-30",{"date":295,"type":53},{"date":402,"type":53},"2024-06-25",{"date":186,"type":22},{"name":405,"class":406},"Sichuan Baili Pharmaceutical Co., Ltd.","INDUSTRY",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":414,"targetDuration":4,"studyType":23,"phases":416,"briefSummary":417,"conditions":418,"keywords":419,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":61},"100435031","phase-3-camrelizumab-plus-stereotactic-body-radiotherapy-vs-camrelizumab-alone-for-oligometastatic-nasopharyngeal-carcinoma-100435031","NCT04944914","Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma","Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma: A Multicenter Randomized Clinical Phase 3 Trial","Inclusion Criteria:\n\n1. Male or female; 18-70 years of age.\n2. Primary lesion and regional lymph nodes completed radical radiotherapy 3 months before stereotactic body radiotherapy and diseases well controlled.\n3. Underwent at least first-line systemic chemotherapy, regardless of regimen and curative effect.\n4. Imageological evidence for oligometastatic lesions (metastatic tissue biopsy preferred but not necessary). The number of total metastatic lesions no more than 5 and the number of metastatic lesions within a single organ no more than 3.\n5. ECOG performance status of 0 or 1.\n6. Stereotactic body radiotherapy applicable for all metastatic lesions according to MDT.\n7. If metastatic lesions have received local treatment (surgery, radiofrequency ablation, radiotherapy etc.):\n\n   * Eligible if treated lesion is well controlled according to imageological examinations, and the lesion does not need stereotactic body radiotherapy.\n   * If treated lesion is not controlled according to imageological examinations:\n\n     * Eligible if the treatment is surgery and that stereotactic body radiotherapy is applicable for the treated lesion.\n     * Ineligible if the treatment is radiofrequency ablation or radiotherapy.\n8. Maximum diameter of brain metastatic lesion no more than 3cm.\n9. Maximum diameter of metastatic lesion (brain excluded) no more than 5cm.\n\n   * Maximum diameter of bone metastatic lesion no more than 6cm if attending doctor decides it is safe to apply the treatment.\n10. Life expectancy more than 12 weeks.\n\nExclusion Criteria:\n\n1. Immunotherapy (PD-1\u002FPD-L1 or CTLA-4 monoclonal antibody) failure.\n2. CHD no less than grade 2, arrhythmia (QTc interval over 450ms for male and 470ms for female) or cardiac insufficiency.\n3. History of severe hypersensitivity to any ingredient of PD-1\u002FPD-L1 or other monoclonal antibody.\n4. chemotherapy (cytotoxic or molecular targeted) within 4 weeks before stereotactic body radiotherapy.\n5. Imageological evidence for spinal cord compression, or tumor less than 3mm away from spinal cord.\n6. Patient with brain metastasis who needs decompression surgery.\n7. Other malignancy or malignant hydrothorax.\n8. Concurrent known or suspicious autoimmune disease, including dementia and epilepsy.\n9. Use of large dose corticosteroids within 4 weeks before study drug administration.\n10. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids.\n11. Active tuberculosis (TB), anti-TB treatment is ongoing or within 1 year prior to screening\n12. Subjects with any active autoimmune disease or history of autoimmune disease, or history of syndrome that requires systemic steroids or immunosuppressive medications, including but not limited to the following: rheumatoid arthritis, pneumonitis, colitis (inflammatory bowel disease), hepatitis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma\u002Fatopy.\n13. Has a known history of human immunodeficiency virus (HIV), has hepatitis B surface antigen (HBsAg) positive with hepatitis B virus (HBV) DNA copy number of ≥1000cps\u002Fml or hepatitis C virus (HCV) antibody positive.\n14. Received any anti-infective vaccine (e.g. influenza vaccine, varicella vaccine, etc.) within 4 weeks prior to enrollment.\n15. Pregnancy or lactation.\n16. Other ineligible patients according to attending doctor.",{"count":415,"type":22},188,[202],"We intend to compare the efficacy and safety of immunotherapy plus stereotactic body radiotherapy at oligometastatic lesions and immunotherapy alone among patients with oligometastatic nasopharyngeal carcinoma whose primary lesion has been well controlled after radical local-regional treatment through this multicenter randomized phase 3 trial.",[32],[420,421,422],"Oligometastatic Nasopharyngeal Carcinoma","Immunotherapy","Stereotactic Body Radiotherapy","2026-04-24",{"date":399,"type":53},{"date":426,"type":53},"2021-06-01",{"date":428,"type":22},"2028-06-01",{"name":247,"class":101},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":439,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":4},"100635682","phase-2-becotatug-vedotin-plus-pd-1-monoclonal-antibody-and-radiotherapy-for-unresectable-locally-recurrent-nasopharyngeal-carcinoma-100635682","NCT07555860","Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma","An Open-Label, Single-Arm, Single-Center Phase II Study of Induction Becotatug Vedotin Plus a PD-1 Inhibitor Followed by Radiotherapy With PD-1 Maintenance in Patients With Unresectable Locally Recurrent Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Voluntarily participates in the study and provides written informed consent.\n* Aged 18-70 years, male or non-pregnant female, with an expected survival of ≥3 months and an ECOG performance status of 0 or 1.\n* Histologically or cytologically confirmed locally recurrent nasopharyngeal carcinoma, differentiated or undifferentiated carcinoma, corresponding to WHO type II or III, with clinical stage rT2-4N0-3M0, rIA-III according to the AJCC 9th edition.\n* Recurrence occurring more than 12 months after completion of initial radiotherapy, with no systemic or local antitumor treatment during this interval.\n* At least one measurable lesion according to RECIST v1.1.\n* Hemoglobin ≥90 g\u002FL, white blood cell count ≥4.0 × 10⁹\u002FL, and platelet count ≥100 × 10⁹\u002FL.\n* Adequate liver function: total bilirubin \\\u003C2.0 × ULN; AST and ALT ≤2.5 × ULN in the absence of liver metastasis, or ALT or AST ≤3.0 × ULN in the presence of liver metastasis; ALP ≤1.5 × ULN, or ≤2 × ULN in the presence of liver metastasis; serum albumin ≥30 g\u002FL.\n* Adequate coagulation function: INR or PT and APTT ≤1.5 × ULN, except for patients receiving anticoagulant therapy, whose anticoagulation level should be within the therapeutic range. These laboratory parameters should be closely monitored by the investigator if the patient is receiving anticoagulant therapy.\n* Adequate renal function, defined as serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL\u002Fmin if serum creatinine is \\>1.5 × ULN. Creatinine clearance should be calculated using the corrected Cockcroft-Gault formula.\n* Female and male patients of childbearing potential must agree to use adequate contraception during treatment and for 180 days after the last dose.\n\nExclusion Criteria:\n\n* Patients with surgically resectable locally recurrent disease, including rT2 disease limited to the superficial parapharyngeal space and located more than 0.5 cm from the internal carotid artery, or rT3 disease limited to the floor of the sphenoid sinus and located more than 0.5 cm from the internal carotid artery and cavernous sinus.\n* Nasopharyngeal necrosis, radiation-induced brain injury, severe cervical fibrosis, or other CTCAE v5.0 Grade ≥3 radiation-related complications, with extremely high radiotherapy risk as assessed by the investigator.\n* Grade ≥2 peripheral neuropathy according to CTCAE v5.0.\n* Receipt of systemic chemotherapy within 3 weeks before the first dose of study drug; small-molecule targeted therapy within 2 weeks or 5 half-lives, whichever is longer, before the first dose; antitumor biologic therapy, macromolecular targeted therapy, immunotherapy, or major surgery within 4 weeks before the first dose, except for minor surgery within 2 weeks with complete recovery.\n* Residual toxicity from prior antitumor therapy, including immunotherapy, targeted therapy, chemotherapy, or radiotherapy, except alopecia, fatigue, and Grade 2 hypothyroidism, or clinically significant laboratory abnormalities greater than Grade 1 according to CTCAE v5.0.\n* Uncontrolled or poorly controlled cardiac disease, including congestive heart failure (CHF) Grade ≥2 according to CTCAE v5.0 or New York Heart Association classification, myocardial infarction, unstable angina, history of ventricular tachycardia or torsades de pointes, or arrhythmia requiring treatment within 6 months before enrollment; QTcF \\>450 ms in males or \\>470 ms in females; complete left bundle branch block; or third-degree atrioventricular block. QTcF = QT\u002F(RR\\^0.33).\n* Pulmonary embolism or deep vein thrombosis within 3 months before the first dose of study drug, except catheter-related thrombosis from an infusion port or PICC line.\n* Known history of malignancy, except for radically treated basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, carcinoma in situ, or papillary thyroid carcinoma, unless the patient has received potentially curative treatment and has had no disease recurrence within 5 years after treatment initiation.\n* Any severe or uncontrolled systemic disease, including uncontrolled or poorly controlled hypertension, such as systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg, or diabetes mellitus with HbA1c \\>8%.\n* Active bleeding, history of coagulation disorder, or treatment with coumarin anticoagulants.\n* Known hypersensitivity to any component or excipient of becotatug vedotin, including citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, sodium chloride, and polysorbate 80; or known Grade ≥3 hypersensitivity reaction to prior anti-EGFR drugs, including investigational study drugs, or other monoclonal antibodies.\n* Known active hepatitis B or hepatitis C. Active hepatitis B is defined as known HBsAg positivity and HBV DNA ≥500 IU\u002FmL. Active hepatitis C is defined as known hepatitis C antibody positivity and quantitative HCV RNA above the lower limit of detection. Other severe liver diseases, including chronic autoimmune liver disease, primary biliary cirrhosis or sclerosing cholangitis, alcoholic liver disease, or nonalcoholic steatohepatitis (NASH), are also excluded.\n* Severe uncontrolled infection; known human immunodeficiency virus (HIV) infection with positive HIV antibody; diagnosis of acquired immunodeficiency syndrome (AIDS); active autoimmune disease, except type 1 diabetes mellitus, hypothyroidism controlled by replacement therapy, and skin diseases not requiring systemic therapy, such as vitiligo, psoriasis, or alopecia; prior allogeneic tissue or organ transplantation, stem cell or bone marrow transplantation, or prior solid organ transplantation.\n* Active bacterial, viral, fungal, rickettsial, or parasitic infection requiring systemic anti-infective therapy, unless treated and resolved before study drug administration.\n* Receipt of a live viral vaccine within 30 days before the first dose of study drug.\n* History of or concurrent interstitial pneumonia, severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary insufficiency, symptomatic bronchospasm, or similar pulmonary conditions.\n* Receipt of immunology-based therapy for any reason, including chronic systemic steroid therapy equivalent to \\>10 mg\u002Fday prednisone within 7 days before the first dose of study drug or at any time during the study. Inhaled or topical steroids, systemic corticosteroids equivalent to ≤10 mg\u002Fday prednisone, and short-term corticosteroids equivalent to \\>10 mg\u002Fday prednisone, such as premedication before contrast administration, are permitted.\n* Uncontrolled pleural, abdominal, pelvic, or pericardial effusion requiring drainage at least once per month.\n* Positive pregnancy test or breastfeeding. Female and male patients who do not plan to use adequate contraception during treatment and for 180 days after the last dose are excluded.\n* Any other disease, clinically significant laboratory abnormality, severe medical or psychiatric condition, or substance abuse including alcoholism that, in the investigator's opinion, may compromise patient safety, study integrity, patient participation, or interfere with the study objectives and outcome analysis.",{"count":438,"type":22},28,[26],"This exploratory clinical study will enroll patients with unresectable locally recurrent nasopharyngeal carcinoma to receive two cycles of becotatug vedotin plus a PD-1 monoclonal antibody, followed by sequential radiotherapy and PD-1 monoclonal antibody maintenance until disease progression or unacceptable toxicity. The study aims to evaluate the efficacy and safety of this treatment strategy.",[32],"2026-04-21",{"date":444,"type":53},"2026-04-29",{"date":446,"type":22},"2026-04-20",{"date":448,"type":22},"2029-12-31",{"name":247,"class":101},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":373,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":459,"briefSummary":460,"conditions":461,"keywords":462,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":61},"100634492","phase-3-gapp-induction-and-concurrent-chemoradiotherapy-for-high-risk-locoregionally-advanced-npc-100634492","NCT07540390","GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.","An Open-label, Multicenter, Randomized Controlled Phase III Clinical Trial of PD-1 Monoclonal Antibody Plus Anlotinib Combined With Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma.","Inclusion Criteria:\n\n* Voluntary participation and signed informed consent.\n* Age 18-65 years, male or non-pregnant female.\n* Pathologically confirmed non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., WHO type II or III).\n* Previously untreated patients with no history of other malignancies; initial treatment for nasopharyngeal carcinoma.\n* Stage III: TanyN3M0 \u002F T4N0-2M0 (9th AJCC\u002FUICC staging system).\n* ECOG performance status 0-1, with no severe dysfunction of vital organs (heart, lung, liver, kidney, etc.).\n* Hemoglobin (HGB) ≥90 g\u002FL, white blood cell count (WBC) ≥4.0×10\\^9 \u002FL, platelet count (PLT) ≥100×10\\^9\u002FL.\n* Liver function: ALT and AST \\\u003C2.5× upper limit of normal (ULN); total bilirubin \\\u003C2.0×ULN.\n* Renal function: serum creatinine \\\u003C1.5×ULN.\n\nExclusion Criteria:\n\n* Patients with recurrent or distant metastatic nasopharyngeal carcinoma.\n* Pathologically confirmed keratinizing squamous cell carcinoma (WHO type I).\n* Receipt of systemic or topical glucocorticoid therapy within 4 weeks prior to enrollment.\n* Participation in another clinical trial of an investigational drug within 3 months prior to treatment.\n* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Patients with idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans), radiation pneumonitis that is clinically symptomatic or requires steroid therapy, active pneumonitis, or other moderate-to-severe pulmonary diseases that significantly affect lung function.\n* Comorbidities requiring long-term immunosuppressive medication or systemic\u002Ftopical corticosteroids at immunosuppressive doses.\n* Prior use of anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies (or any other antibodies targeting T-cell co-stimulatory or checkpoint pathways) with documented disease progression at the time of study entry.\n* Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis). Patients with vitiligo or childhood asthma that has completely resolved and requires no intervention in adulthood may be included; patients requiring bronchodilators for medical management of asthma are excluded.\n* HIV-positive; HBsAg-positive with detectable HBV DNA copy number (quantitative detection ≥1000 cps\u002FmL); positive hepatitis C antibody (HCV Ab) with detectable HCV RNA.\n* Receipt of any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine) within 4 weeks prior to enrollment.\n* Positive pregnancy test in women of childbearing potential, or lactating women.\n* Inability to comply with scheduled follow-up due to psychological, social, family, or geographical reasons.",{"count":458,"type":22},442,[202],"The investigators have designed a multicenter, open-label, randomized controlled phase III clinical study of GAPP induction therapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy for high-risk locoregionally advanced nasopharyngeal carcinoma (stage III, AJCC 9th edition). The aim is to obtain high-level, high-quality evidence-based data to clarify the efficacy and safety of combining chemoradiotherapy with PD-1 antibody and anlotinib, thereby providing a new treatment strategy to improve the prognosis of patients with high-risk locoregionally advanced nasopharyngeal carcinoma. In this study, GPP induction chemotherapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy is selected as the control group. This regimen is currently the standard treatment recommended by guidelines for high-risk locoregionally advanced nasopharyngeal carcinoma, with well-established efficacy and broad clinical application. It provides a reliable benchmark for comparing the efficacy and safety of the experimental group, meets ethical requirements, and has mature clinical operational procedures.",[32],[463,464],"Locoregionally advanced","Stage III (AJCC 9th edition)","2026-04-18",{"date":467,"type":53},"2026-04-22",{"date":469,"type":22},"2026-05-08",{"date":471,"type":22},"2032-12-31",{"name":247,"class":101},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":17,"minAge":480,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":23,"phases":484,"briefSummary":485,"conditions":486,"keywords":487,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":502},"100523241","phase-2-tislelizumab-and-metronomic-capecitabine-as-maintenance-in-high-risk-locoregionally-advanced-nasopharyngeal-carcinoma-100523241","NCT06093061","Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma","RIBBON-LA-01: Single-arm, Open-label, Phase 2 Trial of Tislelizumab and Metronomic Capecitabine as Maintenance Therapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments\n2. Age ≥21 years on the day of signing the ICF\n3. LA-NPC defined as AJCC\u002FUICC 8th edition TNM-stage III-IVA\n4. DETECTABLE EBV DNA levels following 3 cycles of IC, defined as \\>0 copies\u002FmL\n5. ECOG Performance Status ≤1\n6. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and ≥120 days after the last dose of tislelizumab, and have a negative urine or serum pregnancy test ≤7 days of start of trial\n7. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥120 days after the last dose of tislelizumab\n\nExclusion Criteria:\n\n1. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137)\n2. Has received any prior radiotherapy (RT) or systemic anti-cancer therapy including investigational agents for NPC, except for induction chemotherapy (Cisplatin and Gemcitabine) that was completed within the last 22 days. Subjects who have started on concurrent chemo-radiotherapy (CCRT; cisplatin with radiotherapy) following completion of induction chemotherapy (Cisplatin with Gemcitabine) are allowed to enroll\n3. Any known central nervous system metastases and\u002For carcinomatous meningitis\n4. Active autoimmune diseases or history of autoimmune diseases that may relapse\n\n   Note: Patients with the following diseases are not excluded and may proceed to further screening:\n   1. Controlled Type I diabetes\n   2. Hypothyroidism (provided it is managed with hormone replacement therapy only)\n   3. Controlled celiac disease\n   4. Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia)\n   5. Any other disease that is not expected to recur in the absence of external triggering factors\n5. Any active malignancy ≤2 years before start of study except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast). Patients with a history of other malignancies may be eligible if both the Principal Investigator and the Investigator Sponsor or designee have assessed and documented that the patient has a low risk of relapse requiring no further treatment, and that participation in the clinical trial will not increase the patient's risk profile\n6. Any condition that required systemic treatment with either corticosteroids (\\>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤14 days before start of study\n\n   Note: Patients who are currently or have previously been on any of the following steroid regimens are not excluded:\n   1. Adrenal replacement steroid (dose ≤10 mg daily of prednisone or equivalent)\n   2. Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption\n   3. Short course (≤7 days) of corticosteroid prescribed prophylactically (e.g., for contrast dye allergy) or for the treatment of a non-autoimmune condition (e.g., delayed-type hypersensitivity reaction caused by contact allergen)\n7. With uncontrolled diabetes or \\>Grade 1 laboratory test abnormalities in potassium, sodium, or corrected calcium despite standard medical management or ≥Grade 3 hypoalbuminemia ≤14 days before start of study\n8. With history of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc.\n9. With severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, etc.\n\n   1. Severe infections within 4 weeks before start of study, including but not limited to hospitalization for complications of infection, bactiraemia, or severe pneumonia.\n   2. Received therapeutic oral or intravenous antibiotics within 2 weeks before start of study.\n10. A known history of HIV infection\n11. Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers whose HBV DNA is \\>500 IU\u002FmL or patients with active hepatitis C virus (HCV) should be excluded. Note: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA \\\u003C500 IU\u002FmL), and cured hepatitis C patients can be enrolled\n12. Any major surgical procedure requiring general anaesthesia ≤28 days before start of study\n13. Prior allogeneic stem cell transplantation or organ transplantation\n14. Any of the following cardiovascular risk factors:\n\n    1. Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily living, ≤28 days before start of study\n    2. Pulmonary embolism ≤28 days before start of study\n    3. Any history of acute myocardial infarction ≤6 months before start of study\n    4. Any history of heart failure meeting New York Heart Association (NYHA) Classification III or IV ≤6 months before start of study\n    5. Any event of ventricular arrhythmia ≥Grade 2 in severity ≤6 months before start of study\n    6. Any history of cerebrovascular accident ≤6 months before start of study\n    7. Uncontrolled hypertension: systolic pressure ≥160 mmHg or diastolic pressure ≥100 mmHg despite anti-hypertension medications ≤28 days before start of study\n    8. Any episode of syncope or seizure ≤28 days before start of study\n15. A history of severe hypersensitivity reactions to tislelizumab, gemcitabine, cisplatin, capecitabine and\u002For any of its excipients\n16. Has received any herbal medicine used to control cancer within 14 days of the start of study\n17. Patients with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized, except for AEs not considered a likely safety risk (e.g., alopecia, neuropathy and specific laboratory abnormalities)\n18. Was administered a live vaccine ≤4 weeks before start of study Note: Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines, and are not allowed\n19. Underlying medical conditions (including laboratory abnormalities) or alcohol or drug abuse or dependence that, will be unfavourable for the administration of study drug or affect the explanation of drug toxicity or AEs or result in insufficient or might impair compliance with study conduct\n20. Concurrent participation in another therapeutic clinical study","21 Years","99 Years",{"count":483,"type":22},53,[26],"Patients with \"high-risk\" locoregionally-advanced nasopharyngeal carcinoma (LA-NPC), defined as AJCC\u002FUICC 8th edition TNM-stage III-IVA and high Epstein-Barr virus (EBV) DNA viral load (≥4,000 copies\u002FmL) will require induction chemotherapy (IC) prior to chemo-radiation (CCRT) as per standard treatment. Patients who persist to manifest DETECTABLE EBV DNA following 3 cycles of IC have a higher risk of relapse, and are typically recommended for a year of low-dose oral chemotherapy after CCRT.\n\nRIBBON-LA-01 is a single-arm, open-label, phase 2 clinical trial of maintenance tislelizumab and metronomic capecitabine (metroCap) for 52 weeks after IC and CCRT, targeting this specific group of patients who have persistent detectable EBV DNA after IC. The main objective is to evaluate the efficacy of maintenance tislelizumab and metroCap in patients with DETECTABLE EBV DNA levels after 3 cycles of IC.",[32],[488,489,490,491,492],"Locoregionally-advanced NPC","EBV DNA","Concurrent chemoradiotherapy (CCRT)","Maintenance Tislelizumab","Metronomic Capecitabine","2026-04-09",{"date":495,"type":53},"2026-04-14",{"date":497,"type":53},"2024-07-03",{"date":499,"type":22},"2029-10",{"name":501,"class":101},"National Cancer Centre, Singapore",2,{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":285,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":511,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":61},"100484400","early-phase-1-clinical-study-on-the-ebv-car-t-tcr-t-cells-in-the-treatment-of-nasopharyngeal-carcinoma-100484400","NCT05587543","Clinical Study on the EBV CAR-T \u002FTCR-T Cells in the Treatment of Nasopharyngeal Carcinoma","Clinical Study on the Safety and Efficacy of EBV CAR-T \u002FTCR-T Cells in the Treatment of Recurrent \u002F Refractory EBV Positive Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Voluntary written informed consent;\n* Age ≥18 years old, ≤75 years old, male and female;\n* Expected survival ≥3 months;\n* The Eastern Cooperative Oncology Group (ECOG) physical fitness score was 0-2;\n* Ebv-positive nasopharyngeal carcinoma was diagnosed by in situ hybridization with Ebers (Eber-fish) .\n* Pathological Paraffin section testing (within 5 years before signing the informed consent form) ;\n* At least one measurable lesion according to RECIST v1.1 criteria for solid tumors;\n* Recurrent\u002Fmetastatic nasopharyngeal carcinoma patients who had previously failed second-line or more systemic therapy;\n* An apheresis or venous access can be established and there are no other contraindications to blood cell isolation；\n* CTCAE 5.0 was lower than grade 1 in the side effects of previous anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, etc.)\n* During the study period and up to 6 months after the end of the administration, fertile subjects -LRB-both male and female) were required to use effective medical contraception. For women of reproductive age, a pregnancy test should be performed within 72 hours before the first dose, and the results were negative.\n\nExclusion Criteria:\n\n* Active central nervous system metastases (except those that are stable after treatment)；\n* HIV positive, HBsAg positive and HBV DNA copy number positive (quantitative detection ≥1000 CPS\u002Fml) , HCV antibody positive and HCV RNA positive;\n* Patients with mental or psychological disorders who can not cooperate with the treatment and evaluation of the curative effect;\n* Subjects with severe autoimmune disease and long-term use of immunosuppressants;\n* Active or uncontrolled infection requiring systemic therapy was present within 14 days prior to enrollment；\n* Any unstable systemic disease;\n* Complicated with dysfunction of important organs such as lung, brain and kidney.\n* Subjects had undergone major surgery or severe trauma within 4 weeks before receiving cell therapy, or were expected to undergo major surgery during the study period.\n* Participants received their last dose of radiation or anti-tumor therapy within 4 weeks of receiving the cell therapy.\n* Participants had or had had other cancers that were incurable for up to 3 years, except for cervical cancer in situ or skin basal-cell carcinoma, and other cancers that had disease-free survival of more than 5 years.\n* Treated with Chimeric antigen receptor t-cell therapy within six months.\n* Graft-versus-host disease (GVHD)；\n* Subjects who were receiving systemic steroid therapy before screening and who required long-term systemic steroid therapy during treatment as determined by the investigator (with the exception of inhaled or topical use) ; And subjects treated with systemic steroids within 72 hours before cell reinfusion (except for inhalation or topical use) .\n* Severe allergies or a history of allergies;\n* Subjects requiring anticoagulant therapy;\n* Pregnant or lactating women, or a six-month pregnancy plan (for both men and women)；\n* Researchers believe there are other reasons not to include people in treatment.",{"count":83,"type":22},[512],"EARLY_PHASE1","This study was a single-arm, open-label, \"3 + 3\" dose-escalation Exploratory research. The patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group. The EBV CAR-T-treated group received three progressively increasing dose levels (3.0 × 106 cells\u002Fkg, 9.0 × 106 cells\u002Fkg, 1.5 × 107 cells\u002Fkg) of EBV CAR-T-cell therapy; The EBV TCR-T-cell group received three progressively increasing doses (5.0 × 106 cells\u002Fkg, 1.5 × 107 cells\u002Fkg, 3.0 × 107 cells\u002Fkg) of EBV TCR-T-cell therapy.",[32],"2026-03-28",{"date":517,"type":53},"2026-04-02",{"date":519,"type":53},"2022-12-28",{"date":521,"type":22},"2030-10",{"name":523,"class":101},"Fudan University",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":533,"briefSummary":534,"conditions":535,"keywords":536,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":4},"100617618","phase-1-chidamide-in-combination-with-toripalimab-and-anlotinib-in-recurrentmetastatic-nasopharyngeal-carcinoma-100617618","NCT07320963","Chidamide in Combination With Toripalimab and Anlotinib in Recurrent\u002FMetastatic Nasopharyngeal Carcinoma.","A Prospective, Single-Arm, Phase Ib\u002FII Clinical Trial of Chidamide in Combination With Toripalimab and Anlotinib in Patients With Recurrent\u002FMetastatic Nasopharyngeal Carcinoma Who Have Failed at Least One Prior Line of Therapy","Inclusion Criteria:\n\n\\- 1. Age: ≥18 years and ≤70 years, gender unrestricted. 2. Diagnosis: Histologically\u002Fpathologically confirmed metastatic nasopharyngeal carcinoma (NPC) that has failed at least one prior line of therapy (including cisplatin-containing regimens) or is intolerant to existing therapies (relapse within 6 months after completion of adjuvant\u002Fneoadjuvant concurrent chemoradiotherapy is eligible).\n\n3\\. Performance Status: ECOG performance status 0-1. Measurable Disease: At least one measurable lesion per RECIST 1.1 criteria. 4. Prior Immunotherapy:\n\nPatients who have received PD-1, PD-L1, PD-L2, or CTLA-4 inhibitors, or other therapies targeting T-cell co-stimulation\u002Fcheckpoint pathways:\n\nMust have achieved complete response (CR), partial response (PR), or stable disease (SD) ≥6 months during treatment.\n\nOnly one prior immunotherapy regimen is allowed (e.g., neoadjuvant and adjuvant regimens using the same immunotherapy are considered one regimen).\n\nSwitching to a different immunotherapy regimen for non-immunotherapy-related progression is permissible if cumulative SD duration ≥6 months.\n\n6\\. Organ Function:\n\nHematology:\n\nANC ≥1.5×10⁹\u002FL, PLT ≥75×10⁹\u002FL, Hb ≥90 g\u002FL. No blood product transfusion or growth factor support (e.g., G-CSF, EPO) within 2 weeks prior to screening.\n\nHepatology:\n\nTBIL ≤1.5×ULN; ALT\u002FAST ≤2.5×ULN (≤5×ULN if liver metastases present).\n\nRenal Function:\n\nSerum Cr ≤1.5×ULN or CrCl \\>60 mL\u002Fmin.\n\nThyroid Function:\n\nTSH, FT4, FT3 within CTC AE Grade 0-1. 7. Survival Expectancy: ≥3 months. 8. Informed Consent: Voluntary participation and signed written informed consent.\n\nExclusion Criteria:\n\n1. Known severe hypersensitivity (≥Grade 3) to any monoclonal\u002Fpolyclonal antibody, chidamide, or anlotinib components.\n2. Necrotic lesions identified within 4 weeks prior to enrollment, with investigator-judged risk of major bleeding.\n3. Chemotherapy, targeted therapy, or immunomodulatory agents (including thymosin, interferon, IL-2, etc.) within 2 weeks prior to enrollment.\n\n   Washout period determined by clinical resolution of adverse events (AEs) and prior treatment regimens.\n4. Palliative radiotherapy to localized lesions within 4 weeks prior to enrollment, unless the lesion is non-target and other measurable target lesions exist.\n5. Grade ≥3 irAEs during prior immunotherapy.\n6. Prior treatment with HDAC inhibitors or anti-angiogenic agents.\n7. Urine protein ≥2+ or 24-hour urinary protein ≥1 g.\n8. Systolic BP \\>140 mmHg or diastolic BP \\>90 mmHg despite treatment.\n9. Persistent toxicity from prior antitumor therapy (per NCI CTCAE v5.0) \\>Grade 1, excluding: alopecia, Grade 2 fatigue, Grade 2 anemia, or asymptomatic lab abnormalities.\n10. Symptomatic CNS metastases (e.g., edema, steroid requirement) or leptomeningeal disease.\n11. Systemic immunosuppressive drugs (excluding topical\u002Finhaled corticosteroids or physiological doses ≤10 mg\u002Fday prednisone equivalent) or corticosteroids for contrast allergy within 4 weeks prior to enrollment.\n12. Active autoimmune diseases (e.g., interstitial pneumonia, colitis, thyroiditis) or history of severe autoimmune conditions requiring systemic therapy.\n\n    Exceptions: Vitiligo, childhood asthma (resolved without treatment), or mild asthma managed without bronchodilators.\n13. Ongoing anti-tuberculosis therapy or treatment within 1 year prior to screening.\n14. Conditions requiring long-term immunosuppressive therapy or systemic corticosteroids at immunosuppressive doses.\n15. Severe Cardiac Disease or Significant Cardiac Symptoms.\n16. Other Circumstances Deemed Unsuitable by the Investigator",{"count":532,"type":22},52,[25,26],"To explore and evaluate the dose-limiting toxicity (DLT) profile of the fixed-dose combination of toripalimab, anlotinib, and chidamide in patients with recurrent\u002Fmetastatic nasopharyngeal carcinoma (R\u002FM NPC), and to determine the maximum tolerated dose (MTD) of chidamide, thereby informing subsequent clinical dosing regimens.\n\nTo assess the objective response rate (ORR) of the combination regimen in this patient population.",[32],[537,294,538,539,540],"HDACi","NPC","chidamide","anti-angiogenesis","2026-03-17",{"date":543,"type":53},"2026-03-20",{"date":545,"type":22},"2026-03-31",{"date":547,"type":22},"2028-03-28",{"name":247,"class":101},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":373,"enrollmentInfo":556,"targetDuration":4,"studyType":23,"phases":558,"briefSummary":559,"conditions":560,"keywords":561,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":577},"100534507","phase-3-reduced-dose-radiotherapy-for-stage-iii-nasopharyngeal-carcinoma-based-on-the-treatment-response-100534507","NCT06239727","Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response: an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial","Inclusion Criteria:\n\n1. Age: 18 Years to 65 Years;\n2. Eastern Cooperative Oncology Group performance status ≤1;\n3. Patients with newly diagnosed, histologically confirmed nasopharyngeal carcinoma, the pathological type is non-keratinising carcinoma;\n4. Tumor staged as Stage III (T3N0 Excepted; AJCC 8th);\n5. Patients' lymph node without adverse features (no central necrosis, no muscle\u002Fskin invasion, no lymph node fusion);\n6. Normal bone marrow function: white blood cell count \\> 4×10\\^9\u002FL, hemoglobin \\> 90g\u002FL, platelet count \\> 100×10\\^9\u002FL;\n7. Normal liver and kidney function: total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine transaminase and aspartate transaminase ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN, creatinine clearance rate ≥ 60 ml\u002Fmin;\n8. Receive 3 cycles of indction chemotherapy (GP regimen + Camrelizumab);\n9. Plasma EBV DNA after the second cycle of concurrent chemotherapy: negative;\n10. Complete remission after 27 fractions of radiotherapy based on the MRI examination of the nasopharynx and neck (According to Response Evaluation Criteria in Solid Tumors 1.1);\n11. Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule;\n12. Subjects with pregnancy ability must agree to use reliable contraceptive measures from screening to 1 year after treatment.\n\nExclusion Criteria:\n\n1. Hepatitis B virus surface antigen (HBsAg) positive and Hepatitis B virus DNA \\> 1000 copies\u002Fml;\n2. Anti-hepatitis C virus positive;\n3. Anti-human immunodeficiency virus (HIV) positive or diagnosed with acquired immune deficiency syndrome (AIDS);\n4. Active tuberculosis: active tuberculosis in the past 1 year should be excluded regardless with treatment, history of active tuberculosis over 1 year should be excluded except that previous regulatory anti-tuberculosis treatment is proved;\n5. Active, known or suspected autoimmune disease (including but not limited to uveitis, enteritis, hepatitis, pituitary, nephritis, vasculitis, hyperthyroidism, hypothyroidism and asthma requiring bronchiectasis). Exceptions are type I diabetes mellitus, hypothyroidism requiring hormone replacement therapy, skin disorders requiring no systemic treatment (such as vitiligo, psoriasis or alopecia);\n6. Previous interstitial lung disease or pneumonia requiring oral or intravenous steroid therapy;\n7. Chronic treatment with systemic glucocorticoid (dose equivalent to or over 10 mg prednisone per day) or any other form of immunosuppressive therapy. Subjects who used inhaled or topical corticosteroids were eligible;\n8. Uncontrolled heart disease, for example: 1) heart failure (NYHA level ≥ 2), 2) unstable angina, 3) myocardial infarction in past 1 year, 4) supraventricular or ventricular arrhythmia requiring treatment or intervention;\n9. Active infection requiring systemic treatment;\n10. Previous or concurrent with other malignant tumors, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ and thyroid papillary cancer;\n11. History of radiotherapy, except for non-melanoma skin cancer located outside the target volume of radiotherapy for nasophayngeal carcinoma;\n12. Receive treatment for the local or regional disease other than that specified in the research plan;\n13. Pregnant or lactating women (pregnancy test should be considered for women with sexual life and fertility);\n14. Allergy to macromolecular protein preparations, or any component of Camrelizumab;\n15. Receiving live vaccine within 30 days of the initial Camrelizumab;\n16. Contraindications to MRI examination, for example: claustrophobia, allergy to MRI contrast;\n17. History of psychotropic disease, alcoholism or drug abuse, and other situation assessed by the investigators that may compromise the safety or compliance of patients, such as serious disease requiring timely treatment (including mental illness), severe laboratory abnormalities, or family-social risk factors.",{"count":557,"type":22},593,[202],"This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication compared with conventional-dose radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage III NPC patients screened out according to the treatment response.",[32],[335,562,563,334,564,565,566,567,568],"Dose","PD-1","Capecitabine","Quality of Life","Personalised Therapy","Complication","Deintensification","2026-03-04",{"date":571,"type":53},"2026-03-06",{"date":573,"type":53},"2024-03-01",{"date":575,"type":22},"2030-02-20",{"name":247,"class":101},26,{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":373,"enrollmentInfo":585,"targetDuration":4,"studyType":23,"phases":587,"briefSummary":588,"conditions":589,"keywords":590,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":61},"100520645","phase-2-envafolimab-combined-with-chemoradiotherapy-and-recombinant-human-endostatin-for-la-npc-100520645","NCT06059261","Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.","A Prospective, Single-arm, Phase II Study of Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin in Locally Advanced Nasopharyngeal Carcinoma.","Inclusion Criteria:\n\n1. ECOG score 0-1.\n2. Aged 18-65 years, male or non-pregnant female;\n3. Pathologically confirmed diagnosis of nasopharyngeal non-keratinizing carcinoma (differentiated or undifferentiated, WHO type II or III) without the need to detect MSI and dMMR status.\n4. high-risk locally advanced stage III-IVA (8th AJCC\u002FUICC staging), i.e., T4N+ or N2-3, or pretreatment EBV-DNA ≥4000 copies\u002Fml, or lymph node extra-envelope invasion grade 3 (invasion of muscle skin, etc.), treatment-naive nasopharyngeal carcinoma patients.\n5. MRI data of nasopharynx and neck before enrollment, and measurable lesions;\n6. Agree to provide a previously stored tumor tissue specimen or biopsy to collect tumor lesion tissue and send it to the central laboratory for PD-L1 IHC testing.\n7. Agree to undergo EBV antibody and EBV-DNA quantitative testing before receiving treatment.\n8. Hematology: WBC ≥ 4000\u002FμL, neutrophils ≥ 2.000\u002FμL, hemoglobin ≥ 9 g\u002FdL, platelets ≥ 100,000\u002FμL;\n9. Liver function: ALT, AST \\\u003C 1.5 times the upper limit of normal (ULN), total bilirubin \\\u003C 1.5 × ULN;\n10. Renal function: serum creatinine \\\u003C 1.5 × ULN.\n11. Patients have signed the informed consent form and are willing and able to comply with the study plan visits, treatment plan, laboratory tests and other study procedures;\n\nExclusion Criteria:\n\n1. Patients with recurrent nasopharyngeal carcinoma and distant metastasis.\n2. Pathology was keratinizing squamous cell carcinoma (WHO classification type I).\n3. Patients who have undergone radiotherapy or systemic chemotherapy;\n4. Pregnant or lactating women, in the reproductive period without effective contraceptive measures;\n5. HIV positive.\n6. Having had other malignancies (except cured basal cell carcinoma or cervical carcinoma in situ);\n7. Patients who have been treated with inhibitors of immune regulatory points (CTLA-4, PD-1, PD-L1, etc.);\n8. Patients need long-term use of immunosuppressive drug therapy, or systemic or local use of immunosuppressive doses of corticosteroids complications;\n9. Patients with immunodeficiency disease, history of organ transplantation (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism; patients with vitiligo or complete remission of asthma in childhood, without any intervention after adulthood can be included; patients with asthma requiring bronchodilators for medical intervention can not be included;\n10. Use of excessive doses of glucocorticoids within 4 weeks.\n11. Laboratory test values within 7 days before enrollment do not meet the relevant criteria;\n12. Patients with significantly low heart, liver, lung, kidney and bone marrow function.\n13. Any other diseases or conditions are contraindications to recombinant human vascular endothelial inhibitors, chemoradiotherapy, immunotherapy (such as active phase of infection, within 6 months after myocardial infarction, symptomatic heart disease including unstable angina pectoris, congestive heart failure or uncontrolled arrhythmia, immunosuppressive therapy);\n14. Any arterial thrombosis, embolism or ischemia within 6 months before inclusion for treatment, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack;\n15. Severe, uncontrolled medical illness and infection.\n16. Concurrent use of other investigational drugs or ongoing other clinical trials;\n17. Refusing or unable to sign the informed consent form to participate in the trial.\n18. Personality or mental disorders, no civil capacity or limited civil capacity;\n19. Hepatitis B surface antigen (HBsAg) positive and peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA) ≥ 1000cps\u002Fml.\n20. Patients who tested positive for HCV antibody were included in the study only if they tested negative for HCV RNA by polymerase chain reaction.",{"count":586,"type":22},30,[26],"This is a single-center, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally advanced nasopharyngeal carcinoma.",[32],[32],"2026-02-14",{"date":593,"type":53},"2026-02-18",{"date":595,"type":22},"2026-02-09",{"date":597,"type":22},"2027-02-01",{"name":599,"class":101},"Chongqing University Cancer Hospital",{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":607,"targetDuration":4,"studyType":312,"phases":4,"briefSummary":609,"conditions":610,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":4},"100623632","crossroad-treatment-regimen-switch---re-induction-chemotherapy-vs-direct-radiotherapy-in-lanpc-with-inadequate-response-to-induction-chemotherapy-100623632","NCT07399158","CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction Chemotherapy","CROSSROAD: A Prospective Multicenter Observational Study on the Efficacy of Treatment Regimen Switch With Re-induction Chemotherapy Versus Direct Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma Patients With Inadequate Response (SD\u002FPD) After Induction Chemotherapy","Inclusion Criteria:\n\nAge: 18 to 70 years old.\n\nHistologically confirmed non-keratinizing nasopharyngeal carcinoma (WHO Type II\u002FIII).\n\nInitial treatment with no distant metastasis: Locally advanced nasopharyngeal carcinoma (according to the AJCC\u002FUICC 9th edition staging, stage II-III, i.e., T3-4N0-3M0 or T1-2N2-3M0).\n\nCompletion of two cycles of standard induction chemotherapy (such as TPF, GP, TP, etc.).\n\nPost-induction chemotherapy evaluation: Disease stability (SD) or disease progression (PD) after two cycles of induction chemotherapy, as assessed by RECIST 1.1 criteria, based on enhanced MRI of the nasopharynx.\n\nECOG Performance Status (PS): 0-1.\n\nBone marrow, liver, and kidney function: Sufficient to tolerate concurrent chemoradiotherapy (specific criteria to be referenced).\n\nInformed consent: Voluntary participation in the study and signing of written informed consent.\n\nExclusion Criteria:\n\nHistory of head and neck tumor radiotherapy or any other malignant cancer history (except for cured non-melanoma skin cancer).\n\nPartial response (PR) or complete response (CR) after induction chemotherapy.\n\nSevere uncontrolled comorbidities, such as unstable angina, congestive heart failure, severe chronic obstructive pulmonary disease (COPD), or uncontrolled diabetes mellitus.\n\nActive infection or severe immunodeficiency diseases.\n\nPregnant or breastfeeding women.\n\nAny mental or social disorders that may interfere with study evaluation or compliance.\n\nOther conditions deemed by the investigator to be unsuitable for participation in the study.",{"count":608,"type":22},223,"This study aims to compare the efficacy of two treatment strategies-re-induction chemotherapy followed by radiotherapy versus direct radiotherapy-in patients with locally advanced nasopharyngeal carcinoma (LANPC) who did not achieve a sufficient response (stable disease or disease progression) after two cycles of induction chemotherapy. The study will enroll patients who have completed two cycles of induction chemotherapy and have not achieved a partial or complete response. Participants will receive one of the two treatment options to evaluate their three-year progression-free survival (PFS) and other clinical outcomes.",[32],"2026-02-07",{"date":613,"type":53},"2026-02-10",{"date":615,"type":22},"2026-02-01",{"date":617,"type":22},"2030-02-01",{"name":619,"class":620},"Fujian Cancer Hospital","OTHER_GOV",{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":628,"targetDuration":4,"studyType":23,"phases":629,"briefSummary":630,"conditions":631,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":639,"locationsCount":4},"100618423","phase-2-mrg003-induction-and-capecitabine-maintenance-with-pd-1-in-locally-recurrent-npc-100618423","NCT07331428","MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC","Efficacy and Safety of MRG003 With PD-1 Induction Followed by Capecitabine and PD-1 Maintenance as First-line Treatment in Locally Recurrent Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n\\*\\*Inclusion Criteria:\\*\\*\n\n1. Patients with locally recurrent nasopharyngeal carcinoma (NPC) more than 1 year after initial radical treatment for non-metastatic NPC, with or without regional recurrence, but without distant metastasis.\n2. Age 18-70 years.\n3. Pathologically confirmed local recurrence of NPC, staged as rT1-rT4 according to the 9th edition of the AJCC\u002FUICC classification.\n4. ECOG performance status score of 0-1.\n5. No prior radiotherapy, chemotherapy, immunotherapy, or biological therapy for recurrent NPC.\n6. No contraindications to immunotherapy or chemotherapy.\n7. Adequate organ function.\n\nExclusion Criteria:\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n1. Previous treatment with other PD-1 antibodies or immunotherapy targeting PD-1\u002FPD-L1 resulting in Grade III or higher immune-related adverse reactions.\n2. Residual toxic effects from prior anti-tumor treatments (including immunotherapy, targeted therapy, chemotherapy, or radiotherapy) (excluding alopecia, fatigue, and Grade 2 hypothyroidism) or clinically significant laboratory abnormalities higher than Grade 1 (CTCAE v5.0).\n3. Congenital or acquired immunodeficiency (e.g., HIV infection), active hepatitis B (HBV-DNA ≥10 copies\u002Fml), or hepatitis C (positive hepatitis C antibody and HCV-RNA above the detection limit of the assay).\n4. Known allergy to MRG003, capecitabine, or any component of anti-PD-1 antibodies.",{"count":7,"type":22},[26],"This study enrolls patients who have experienced local recurrence of nasopharyngeal carcinoma (NPC) with or without regional recurrence. The treatment regimen includes an induction phase with MRG003 at 2.0 mg\u002Fkg (D1) combined with Tislelizumab 200 mg (D1), administered weekly for 6 cycles. This is followed by maintenance therapy consisting of Capecitabine (650 mg\u002Fm², twice daily on days 1-21) in combination with Tislelizumab, continued for up to 1 year or until disease progression.",[32,632],"Local Recurrence","2025-12-28",{"date":635,"type":53},"2026-01-09",{"date":637,"type":22},"2026-01-01",{"date":448,"type":22},{"name":619,"class":620}]